{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:39:54Z","timestamp":1789875594520,"version":"4.0.1"},"reference-count":497,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:00:00Z","timestamp":1491609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["MOP-142235"],"award-info":[{"award-number":["MOP-142235"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00702-017-1722-y","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T09:14:13Z","timestamp":1491642853000},"page":"291-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Non-human primate models of PD to test novel therapies"],"prefix":"10.1007","volume":"125","author":[{"given":"Marc","family":"Morissette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,8]]},"reference":[{"issue":"2","key":"1722_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nprot.2009.241","volume":"5","author":"T Aasen","year":"2010","unstructured":"Aasen T, Izpisua Belmonte JC (2010) Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat Protoc 5(2):371\u2013382. doi: 10.1038\/nprot.2009.241","journal-title":"Nat Protoc"},{"issue":"Suppl 1","key":"1722_CR2","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/mds.870040514","volume":"4","author":"Y Agid","year":"1989","unstructured":"Agid Y, Cervera P, Hirsch E, Javoy-Agid F, Lehericy S, Raisman R, Ruberg M (1989) Biochemistry of Parkinson\u2019s disease 28\u00a0years later: a critical review. Mov Disord 4(Suppl 1):S126\u2013144","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448\u2013458","journal-title":"Mov Disord"},{"key":"1722_CR4","doi-asserted-by":"publisher","unstructured":"Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, Dovero S, Doudnikoff E, Gurevich VV, Gurevich EV, Bezard E (2010) Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson\u2019s disease. Sci Transl Med 2 (28):28ra28. doi: 10.1126\/scitranslmed.3000664","DOI":"10.1126\/scitranslmed.3000664"},{"issue":"2","key":"1722_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cne.10689","volume":"461","author":"Y Ai","year":"2003","unstructured":"Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, Gash DM (2003) Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461(2):250\u2013261. doi: 10.1002\/cne.10689","journal-title":"J Comp Neurol"},{"issue":"1\u20132","key":"1722_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0304-3940(88)90143-7","volume":"87","author":"A Albanese","year":"1988","unstructured":"Albanese A, Jenner P, Marsden CD, Stephenson JD (1988) Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci Lett 87(1\u20132):46\u201350","journal-title":"Neurosci Lett"},{"issue":"3","key":"1722_CR7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0306-4522(93)90444-K","volume":"55","author":"A Albanese","year":"1993","unstructured":"Albanese A, Granata R, Gregori B, Piccardi MP, Colosimo C, Tonali P (1993) Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. Neuroscience 55(3):823\u2013832","journal-title":"Neuroscience"},{"issue":"10","key":"1722_CR8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12(10):366\u2013375","journal-title":"Trends Neurosci"},{"issue":"1","key":"1722_CR9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6","volume":"16","author":"L Alvarez","year":"2001","unstructured":"Alvarez L, Macias R, Guridi J, Lopez G, Alvarez E, Maragoto C, Teijeiro J, Torres A, Pavon N, Rodriguez-Oroz MC, Ochoa L, Hetherington H, Juncos J, DeLong MR, Obeso JA (2001) Dorsal subthalamotomy for Parkinson\u2019s disease. Mov Disord 16(1):72\u201378","journal-title":"Mov Disord"},{"issue":"9","key":"1722_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/jnnp.2008.154948","volume":"80","author":"L Alvarez","year":"2009","unstructured":"Alvarez L, Macias R, Pavon N, Lopez G, Rodriguez-Oroz MC, Rodriguez R, Alvarez M, Pedroso I, Teijeiro J, Fernandez R, Casabona E, Salazar S, Maragoto C, Carballo M, Garcia I, Guridi J, Juncos JL, DeLong MR, Obeso JA (2009) Therapeutic efficacy of unilateral subthalamotomy in Parkinson\u2019s disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry 80(9):979\u2013985. doi: 10.1136\/jnnp.2008.154948","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1722_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pbb.2014.10.009","volume":"127","author":"K Ando","year":"2014","unstructured":"Ando K, Inoue T, Itoh T (2014) L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson\u2019s disease model. Pharmacol Biochem Behav 127:62\u201369. doi: 10.1016\/j.pbb.2014.10.009","journal-title":"Pharmacol Biochem Behav"},{"issue":"Pt 3","key":"1722_CR12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/brain\/115.3.825","volume":"115","author":"LE Annett","year":"1992","unstructured":"Annett LE, Rogers DC, Hernandez TD, Dunnett SB (1992) Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 115(Pt 3):825\u2013856","journal-title":"Brain"},{"issue":"3","key":"1722_CR13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0306-4522(90)90059-D","volume":"38","author":"P Apicella","year":"1990","unstructured":"Apicella P, Trouche E, Nieoullon A, Legallet E, Dusticier N (1990) Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys. Neuroscience 38(3):655\u2013666","journal-title":"Neuroscience"},{"key":"1722_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejphar.2015.03.038","volume":"759","author":"R Aron Badin","year":"2015","unstructured":"Aron Badin R, Vadori M, Cozzi E, Hantraye P (2015) Translational research for Parkinsons disease: the value of pre-clinical primate models. Eur J Pharmacol 759:118\u2013126. doi: 10.1016\/j.ejphar.2015.03.038","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"1722_CR15","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson\u2019s disease: risk factors and prevention. Lancet Neurol 15(12):1257\u20131272. doi: 10.1016\/S1474-4422(16)30230-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"1722_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.20296","volume":"57","author":"I Aubert","year":"2005","unstructured":"Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57(1):17\u201326. doi: 10.1002\/ana.20296","journal-title":"Ann Neurol"},{"issue":"4","key":"1722_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.870060404","volume":"6","author":"TZ Aziz","year":"1991","unstructured":"Aziz TZ, Peggs D, Sambrook MA, Crossman AR (1991) Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 6(4):288\u2013292. doi: 10.1002\/mds.870060404","journal-title":"Mov Disord"},{"issue":"2","key":"1722_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3171\/jns.1985.62.2.0169","volume":"62","author":"EO Backlund","year":"1985","unstructured":"Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Seiger A, Olson L (1985) Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 62(2):169\u2013173. doi: 10.3171\/jns.1985.62.2.0169","journal-title":"First clinical trials. J Neurosurg"},{"issue":"2","key":"1722_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.expneurol.2011.06.012","volume":"231","author":"KB Baker","year":"2011","unstructured":"Baker KB, Zhang J, Vitek JL (2011) Pallidal stimulation: effect of pattern and rate on bradykinesia in the non-human primate model of Parkinson\u2019s disease. Exp Neurol 231(2):309\u2013313. doi: 10.1016\/j.expneurol.2011.06.012","journal-title":"Exp Neurol"},{"issue":"5","key":"1722_CR20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1523\/JNEUROSCI.2010-15.2016","volume":"36","author":"B Ballanger","year":"2016","unstructured":"Ballanger B, Beaudoin-Gobert M, Neumane S, Epinat J, Metereau E, Duperrier S, Broussolle E, Thobois S, Bonnefoi F, Tourvielle C, Lavenne F, Costes N, Lebars D, Zimmer L, Sgambato-Faure V, Tremblay L (2016) Imaging Dopamine and Serotonin Systems on MPTP Monkeys: a Longitudinal PET Investigation of Compensatory Mechanisms. J Neurosci 36(5):1577\u20131589. doi: 10.1523\/JNEUROSCI.2010-15.2016","journal-title":"J Neurosci"},{"issue":"7","key":"1722_CR21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","volume":"35","author":"PA Ballard","year":"1985","unstructured":"Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35(7):949\u2013956","journal-title":"Neurology"},{"issue":"1","key":"1722_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0024-3205(86)90431-5","volume":"39","author":"KS Bankiewicz","year":"1986","unstructured":"Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 39(1):7\u201316","journal-title":"Life Sci"},{"issue":"1","key":"1722_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/exnr.2000.7408","volume":"164","author":"KS Bankiewicz","year":"2000","unstructured":"Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164(1):2\u201314. doi: 10.1006\/exnr.2000.7408","journal-title":"Exp Neurol"},{"issue":"4","key":"1722_CR24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","volume":"14","author":"KS Bankiewicz","year":"2006","unstructured":"Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, Herscovitch P, Carson RE, Eckelman W, Reutter B, Cunningham J (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14(4):564\u2013570. doi: 10.1016\/j.ymthe.2006.05.005","journal-title":"Mol Ther"},{"issue":"10","key":"1722_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/mds.20124","volume":"19","author":"W Bara-Jimenez","year":"2004","unstructured":"Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN (2004) Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson\u2019s disease. Mov Disord 19(10):1183\u20131186. doi: 10.1002\/mds.20124","journal-title":"Mov Disord"},{"issue":"9","key":"1722_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","volume":"11","author":"RA Barker","year":"2015","unstructured":"Barker RA, Drouin-Ouellet J, Parmar M (2015) Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol 11(9):492\u2013503. doi: 10.1038\/nrneurol.2015.123","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1722_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.expneurol.2009.07.019","volume":"219","author":"Q Barraud","year":"2009","unstructured":"Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I (2009) Sleep disorders in Parkinson\u2019s disease: the contribution of the MPTP non-human primate model. Exp Neurol 219(2):574\u2013582. doi: 10.1016\/j.expneurol.2009.07.019","journal-title":"Exp Neurol"},{"key":"1722_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2016.03.027","author":"RT Bartus","year":"2016","unstructured":"Bartus RT, Johnson EM Jr (2016a) Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned? Neurobiol Dis. doi: 10.1016\/j.nbd.2016.03.027","journal-title":"Neurobiol Dis"},{"key":"1722_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2016.03.026","author":"RT Bartus","year":"2016","unstructured":"Bartus RT, Johnson EM Jr (2016b) Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: where do we stand and where must we go next? Neurobiol Dis. doi: 10.1016\/j.nbd.2016.03.026","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1722_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.23442","volume":"26","author":"RT Bartus","year":"2011","unstructured":"Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM Jr, Olanow CW, Mufson EJ, Kordower JH (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains. Mov Disord 26(1):27\u201336. doi: 10.1002\/mds.23442","journal-title":"Mov Disord"},{"key":"1722_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.nbd.2015.03.023","volume":"78","author":"RT Bartus","year":"2015","unstructured":"Bartus RT, Kordower JH, Johnson EM Jr, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD (2015) Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with alpha-synucleinopathies. Neurobiol Dis 78:162\u2013171. doi: 10.1016\/j.nbd.2015.03.023","journal-title":"Neurobiol Dis"},{"key":"1722_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdere P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bezard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog Neurobiol 132:96\u2013168. doi: 10.1016\/j.pneurobio.2015.07.002","journal-title":"Prog Neurobiol"},{"issue":"2","key":"1722_CR33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","volume":"379","author":"PJ Bedard","year":"1986","unstructured":"Bedard PJ, Di Paolo T, Falardeau P, Boucher R (1986) Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 379(2):294\u2013299","journal-title":"Brain Res"},{"issue":"1 Suppl","key":"1722_CR34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0317167100041500","volume":"19","author":"PJ Bedard","year":"1992","unstructured":"Bedard PJ, Mancilla BG, Blanchette P, Gagnon C, Di Paolo T (1992) Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 19(1 Suppl):134\u2013137","journal-title":"Can J Neurol Sci"},{"key":"1722_CR35","doi-asserted-by":"crossref","unstructured":"B\u00e9dard PJ, Boucher R, Gomez-Mancilla B, Blanchette P (1992) Primate models of Parkinson\u2019s disease. In: Boulton AA, Baker GB, Butterworth RF (eds) Animal Models of Neurological Disease, I. vol 21. Humana Press, pp 159-173","DOI":"10.1385\/0-89603-208-6:159"},{"issue":"27","key":"1722_CR36","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.1523\/JNEUROSCI.0181-14.2014","volume":"34","author":"H Belaid","year":"2014","unstructured":"Belaid H, Adrien J, Laffrat E, Tande D, Karachi C, Grabli D, Arnulf I, Clark SD, Drouot X, Hirsch EC, Francois C (2014) Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion. J Neurosci 34(27):9124\u20139133. doi: 10.1523\/JNEUROSCI.0181-14.2014","journal-title":"J Neurosci"},{"issue":"1\u20136","key":"1722_CR37","first-page":"344","volume":"50","author":"AL Benabid","year":"1987","unstructured":"Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J (1987) Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50(1\u20136):344\u2013346","journal-title":"Appl Neurophysiol"},{"key":"1722_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0079-6123(09)17525-8","volume":"175","author":"AL Benabid","year":"2009","unstructured":"Benabid AL, Chabardes S, Torres N, Piallat B, Krack P, Fraix V, Pollak P (2009) Functional neurosurgery for movement disorders: a historical perspective. Prog Brain Res 175:379\u2013391. doi: 10.1016\/S0079-6123(09)17525-8","journal-title":"Prog Brain Res"},{"issue":"4","key":"1722_CR39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1460-9568.1993.tb00505.x","volume":"5","author":"A Benazzouz","year":"1993","unstructured":"Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5(4):382\u2013389","journal-title":"Eur J Neurosci"},{"issue":"3","key":"1722_CR40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(95)00362-O","volume":"284","author":"A Benazzouz","year":"1995","unstructured":"Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284(3):299\u2013307","journal-title":"Eur J Pharmacol"},{"key":"1722_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fnagi.2014.00087","volume":"6","author":"A Benazzouz","year":"2014","unstructured":"Benazzouz A, Mamad O, Abedi P, Bouali-Benazzouz R, Chetrit J (2014) Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson\u2019s disease. Front Aging Neurosci 6:87. doi: 10.3389\/fnagi.2014.00087","journal-title":"Front Aging Neurosci"},{"issue":"Pt 1","key":"1722_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.expneurol.2015.11.004","volume":"275","author":"M Bensaid","year":"2016","unstructured":"Bensaid M, Michel PP, Clark SD, Hirsch EC, Francois C (2016) Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson\u2019s disease. Exp Neurol 275(Pt 1):209\u2013219. doi: 10.1016\/j.expneurol.2015.11.004","journal-title":"Exp Neurol"},{"issue":"Pt 1","key":"1722_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/brain\/awn291","volume":"132","author":"Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN, Group NS","year":"2009","unstructured":"Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN, Group NS (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132(Pt 1):156\u2013171. doi: 10.1093\/brain\/awn291","journal-title":"Brain"},{"issue":"7","key":"1722_CR44","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/mds.23616","volume":"26","author":"D Berg","year":"2011","unstructured":"Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26(7):1243\u20131250. doi: 10.1002\/mds.23616","journal-title":"Mov Disord"},{"issue":"4","key":"1722_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/mds.25844","volume":"29","author":"D Berg","year":"2014","unstructured":"Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson\u2019s disease. Mov Disord 29(4):454\u2013462. doi: 10.1002\/mds.25844","journal-title":"Mov Disord"},{"issue":"4975","key":"1722_CR46","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2402638","volume":"249","author":"H Bergman","year":"1990","unstructured":"Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249(4975):1436\u20131438","journal-title":"Science"},{"issue":"2","key":"1722_CR47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/jn.1994.72.2.507","volume":"72","author":"H Bergman","year":"1994","unstructured":"Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72(2):507\u2013520","journal-title":"J Neurophysiol"},{"issue":"4","key":"1722_CR48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415\u2013455","journal-title":"J Neurol Sci"},{"issue":"12","key":"1722_CR49","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1523\/JNEUROSCI.17-12-04752.1997","volume":"17","author":"S Berretta","year":"1997","unstructured":"Berretta S, Parthasarathy HB, Graybiel AM (1997) Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J Neurosci 17(12):4752\u20134763","journal-title":"J Neurosci"},{"issue":"8","key":"1722_CR50","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE (2001a) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2(8):577\u2013588. doi: 10.1038\/35086062","journal-title":"Nat Rev Neurosci"},{"issue":"17","key":"1722_CR51","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","volume":"21","author":"E Bezard","year":"2001","unstructured":"Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001b) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease. J Neurosci 21(17):6853\u20136861","journal-title":"J Neurosci"},{"issue":"2","key":"1722_CR52","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1006\/nbdi.2000.0375","volume":"8","author":"E Bezard","year":"2001","unstructured":"Bezard E, Ravenscroft P, Gross CE, Crossman AR, Brotchie JM (2001c) Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiol Dis 8(2):343\u2013350. doi: 10.1006\/nbdi.2000.0375","journal-title":"Neurobiol Dis"},{"issue":"6","key":"1722_CR53","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nm875","volume":"9","author":"E Bezard","year":"2003","unstructured":"Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9(6):762\u2013767. doi: 10.1038\/nm875","journal-title":"Nat Med"},{"issue":"1\u20133","key":"1722_CR54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","volume":"485","author":"E Bezard","year":"2004","unstructured":"Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2004) Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 485(1\u20133):159\u2013164","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1722_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","volume":"23","author":"E Bezard","year":"2006","unstructured":"Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (2006) 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson\u2019s disease. Neurobiol Dis 23(1):77\u201386. doi: 10.1016\/j.nbd.2006.02.003","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1722_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","volume":"192","author":"F Bibbiani","year":"2005","unstructured":"Bibbiani F, Costantini LC, Patel R, Chase TN (2005) Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192(1):73\u201378. doi: 10.1016\/j.expneurol.2004.11.013","journal-title":"Exp Neurol"},{"issue":"2","key":"1722_CR57","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(25)24503-7","volume":"272","author":"PJ Blanchet","year":"1995","unstructured":"Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walters RR, Piercey MF (1995) Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272(2):854\u2013859","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1722_CR58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/mds.870110117","volume":"11","author":"PJ Blanchet","year":"1996","unstructured":"Blanchet PJ, Grondin R, Bedard PJ (1996) Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 11(1):91\u201394. doi: 10.1002\/mds.870110117","journal-title":"Mov Disord"},{"issue":"5","key":"1722_CR59","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mds.870130507","volume":"13","author":"PJ Blanchet","year":"1998","unstructured":"Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13(5):798\u2013802. doi: 10.1002\/mds.870130507","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"1722_CR60","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","volume":"14","author":"F Blandini","year":"2008","unstructured":"Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124\u2013129. doi: 10.1016\/j.parkreldis.2008.04.015","journal-title":"Parkinsonism Relat Disord"},{"key":"1722_CR61","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnsys.2011.00092","volume":"5","author":"J Blesa","year":"2011","unstructured":"Blesa J, Juri C, Garcia-Cabezas MA, Adanez R, Sanchez-Gonzalez MA, Cavada C, Obeso JA (2011) Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson\u2019s disease. Front Syst Neurosci 5:92. doi: 10.3389\/fnsys.2011.00092","journal-title":"Front Syst Neurosci"},{"issue":"2","key":"1722_CR62","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","volume":"221","author":"NI Bohnen","year":"2011","unstructured":"Bohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behav Brain Res 221(2):564\u2013573. doi: 10.1016\/j.bbr.2009.12.048","journal-title":"Behav Brain Res"},{"key":"1722_CR63","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbr.2015.01.053","volume":"284","author":"J Boix","year":"2015","unstructured":"Boix J, Padel T, Paul G (2015) A partial lesion model of Parkinson\u2019s disease in mice\u2013characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav Brain Res 284:196\u2013206. doi: 10.1016\/j.bbr.2015.01.053","journal-title":"Behav Brain Res"},{"issue":"2\u20133","key":"1722_CR64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(84)90238-3","volume":"99","author":"B Bokobza","year":"1984","unstructured":"Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) [3H]spiperone binding, dopamine and HVA concentrations in Parkinson\u2019s disease and supranuclear palsy. Eur J Pharmacol 99(2\u20133):167\u2013175","journal-title":"Eur J Pharmacol"},{"key":"1722_CR65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.11.009","volume":"35","author":"J Borgonovo","year":"2017","unstructured":"Borgonovo J, Allende-Castro C, Laliena A, Guerrero N, Silva H, Concha ML (2017) Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson\u2019s disease. Parkinsonism Relat Disord 35:17\u201324. doi: 10.1016\/j.parkreldis.2016.11.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1722_CR66","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.yfrne.2009.04.014","volume":"30","author":"M Bourque","year":"2009","unstructured":"Bourque M, Dluzen DE, Di Paolo T (2009) Neuroprotective actions of sex steroids in Parkinson\u2019s disease. Front Neuroendocrinol 30(2):142\u2013157. doi: 10.1016\/j.yfrne.2009.04.014","journal-title":"Front Neuroendocrinol"},{"issue":"4","key":"1722_CR67","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1096\/fj.07-9677com","volume":"22","author":"M Bousquet","year":"2008","unstructured":"Bousquet M, Saint-Pierre M, Julien C, Salem N Jr, Cicchetti F, Calon F (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson\u2019s disease. FASEB J 22(4):1213\u20131225. doi: 10.1096\/fj.07-9677com","journal-title":"FASEB J"},{"issue":"1","key":"1722_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mds.870050103","volume":"5","author":"S Boyce","year":"1990","unstructured":"Boyce S, Clarke CE, Luquin R, Peggs D, Robertson RG, Mitchell IJ, Sambrook MA, Crossman AR (1990a) Induction of chorea and dystonia in parkinsonian primates. Mov Disord 5(1):3\u20137. doi: 10.1002\/mds.870050103","journal-title":"Mov Disord"},{"issue":"1","key":"1722_CR69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF02245739","volume":"102","author":"S Boyce","year":"1990","unstructured":"Boyce S, Rupniak NM, Steventon MJ, Iversen SD (1990b) Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 102(1):21\u201327","journal-title":"Psychopharmacology"},{"issue":"20","key":"1722_CR70","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/01.wnl.0000312279.49272.9f","volume":"70","author":"H Braak","year":"2008","unstructured":"Braak H, Del Tredici K (2008) Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 70(20):1916\u20131925. doi: 10.1212\/01.wnl.0000312279.49272.9f","journal-title":"Neurology"},{"issue":"2","key":"1722_CR71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24(2):197\u2013211","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1722_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318(1):121\u2013134. doi: 10.1007\/s00441-004-0956-9","journal-title":"Cell Tissue Res"},{"issue":"8","key":"1722_CR73","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.20612","volume":"20","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20(8):919\u2013931. doi: 10.1002\/mds.20612","journal-title":"Mov Disord"},{"issue":"5","key":"1722_CR74","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.21541","volume":"64","author":"RE Burke","year":"2008","unstructured":"Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation of the Braak staging scheme for Parkinson\u2019s disease. Ann Neurol 64(5):485\u2013491. doi: 10.1002\/ana.21541","journal-title":"Ann Neurol"},{"issue":"14","key":"1722_CR75","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80(14):4546\u20134550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1722_CR76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1353-8020(02)00029-9","volume":"8","author":"F Calon","year":"2002","unstructured":"Calon F, Di Paolo T (2002) Levodopa response motor complications\u2013GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord 8(6):449\u2013454","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1722_CR77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","volume":"61","author":"F Calon","year":"2002","unstructured":"Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2002a) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61(2):186\u2013196","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1722_CR78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0278-5846(01)00237-8","volume":"26","author":"F Calon","year":"2002","unstructured":"Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T (2002b) Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26(1):127\u2013138","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"1722_CR79","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/mds.10343","volume":"18","author":"F Calon","year":"2003","unstructured":"Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003a) Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18(3):241\u2013253. doi: 10.1002\/mds.10343","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR80","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","volume":"14","author":"F Calon","year":"2003","unstructured":"Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003b) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson\u2019s disease. Neurobiol Dis 14(3):404\u2013416","journal-title":"Neurobiol Dis"},{"issue":"Pt 5","key":"1722_CR81","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awh128","volume":"127","author":"F Calon","year":"2004","unstructured":"Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias. Brain 127(Pt 5):1075\u20131084. doi: 10.1093\/brain\/awh128","journal-title":"Brain"},{"issue":"2","key":"1722_CR82","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jneumeth.2008.10.026","volume":"177","author":"A Campos-Romo","year":"2009","unstructured":"Campos-Romo A, Ojeda-Flores R, Moreno-Briseno P, Fernandez-Ruiz J (2009) Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task. J Neurosci Methods 177(2):361\u2013368. doi: 10.1016\/j.jneumeth.2008.10.026","journal-title":"J Neurosci Methods"},{"issue":"1","key":"1722_CR83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01244978","volume":"94","author":"ML Carlsson","year":"1993","unstructured":"Carlsson ML (1993) Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (Hypothesis). J Neural Transm Gen Sect 94(1):1\u201310","journal-title":"J Neural Transm Gen Sect"},{"issue":"2","key":"1722_CR84","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","volume":"99","author":"MA Cenci","year":"2006","unstructured":"Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99(2):381\u2013392. doi: 10.1111\/j.1471-4159.2006.04124.x","journal-title":"J Neurochem"},{"issue":"10","key":"1722_CR85","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11910-016-0687-9","volume":"16","author":"A Cerasa","year":"2016","unstructured":"Cerasa A, Novellino F, Quattrone A (2016) Connectivity Changes in Parkinson\u2019s Disease. Curr Neurol Neurosci Rep 16(10):91. doi: 10.1007\/s11910-016-0687-9","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5502","key":"1722_CR86","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.291.5502.309","volume":"291","author":"AW Chan","year":"2001","unstructured":"Chan AW, Chong KY, Martinovich C, Simerly C, Schatten G (2001) Transgenic monkeys produced by retroviral gene transfer into mature oocytes. Science 291(5502):309\u2013312. doi: 10.1126\/science.291.5502.309","journal-title":"Science"},{"key":"1722_CR87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0079-6123(08)63839-X","volume":"88","author":"V Chan-Palay","year":"1991","unstructured":"Chan-Palay V (1991) Alterations in the locus coeruleus in dementias of Alzheimer\u2019s and Parkinson\u2019s disease. Prog Brain Res 88:625\u2013630","journal-title":"Prog Brain Res"},{"key":"1722_CR88","unstructured":"Chase TN, Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47 (4 Suppl 1):S122-129; discussion S129-130"},{"issue":"2","key":"1722_CR89","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2982.2008.01226.x","volume":"21","author":"T Chaumette","year":"2009","unstructured":"Chaumette T, Lebouvier T, Aubert P, Lardeux B, Qin C, Li Q, Accary D, Bezard E, des Bruley Varannes S, Derkinderen P, Neunlist M (2009) Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol Motil 21(2):215\u2013222. doi: 10.1111\/j.1365-2982.2008.01226.x","journal-title":"Neurogastroenterol Motil"},{"key":"1722_CR90","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1998.tb10229.x","volume":"861","author":"CP Chen","year":"1998","unstructured":"Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ (1998) Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson\u2019s disease neocortex. Ann N Y Acad Sci 861:288\u2013289","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"1722_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","volume":"324","author":"W Chen","year":"2013","unstructured":"Chen W, Wang H, Wei H, Gu S, Wei H (2013) Istradefylline, an adenosine A(2)A receptor antagonist, for patients with Parkinson\u2019s Disease: a meta-analysis. J Neurol Sci 324(1\u20132):21\u201328. doi: 10.1016\/j.jns.2012.08.030","journal-title":"J Neurol Sci"},{"issue":"13","key":"1722_CR92","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1093\/hmg\/ddv120","volume":"24","author":"Y Chen","year":"2015","unstructured":"Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X, Tu Z, Si C, Wang H, Xing R, Pu X, Yang SH, Li S, Ji W, Li XJ (2015) Functional disruption of the dystrophin gene in rhesus monkey using CRISPR\/Cas9. Hum Mol Genet 24(13):3764\u20133774. doi: 10.1093\/hmg\/ddv120","journal-title":"Hum Mol Genet"},{"issue":"6","key":"1722_CR93","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"HC Cheng","year":"2010","unstructured":"Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67(6):715\u2013725. doi: 10.1002\/ana.21995","journal-title":"Ann Neurol"},{"issue":"13","key":"1722_CR94","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1097\/00001756-200109170-00017","volume":"12","author":"P Choi","year":"2001","unstructured":"Choi P, Golts N, Snyder H, Chong M, Petrucelli L, Hardy J, Sparkman D, Cochran E, Lee JM, Wolozin B (2001) Co-association of parkin and alpha-synuclein. NeuroReport 12(13):2839\u20132843","journal-title":"NeuroReport"},{"issue":"20","key":"1722_CR95","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20):1662\u20131669. doi: 10.1212\/WNL.0b013e3181c29356","journal-title":"Neurology"},{"issue":"1","key":"1722_CR96","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2006.08.021","volume":"25","author":"Y Chu","year":"2007","unstructured":"Chu Y, Kordower JH (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson\u2019s disease? Neurobiol Dis 25(1):134\u2013149. doi: 10.1016\/j.nbd.2006.08.021","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1722_CR97","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(87)90041-4","volume":"78","author":"CE Clarke","year":"1987","unstructured":"Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR (1987) Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 78(3):273\u2013280","journal-title":"J Neurol Sci"},{"issue":"3","key":"1722_CR98","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02244093","volume":"102","author":"SP Close","year":"1990","unstructured":"Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson\u2019s disease. Psychopharmacology 102(3):295\u2013300","journal-title":"Psychopharmacology"},{"key":"1722_CR99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnins.2016.00012","volume":"10","author":"TJ Collier","year":"2016","unstructured":"Collier TJ, Redmond DE Jr, Steece-Collier K, Lipton JW, Manfredsson FP (2016) Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates. Front Neurosci 10:12. doi: 10.3389\/fnins.2016.00012","journal-title":"Evidence from Non-human Primates. Front Neurosci"},{"issue":"1","key":"1722_CR100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-198403000-00005","volume":"7","author":"DR Cooper","year":"1984","unstructured":"Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P, Marsden CD (1984) L-Dopa methyl ester\u2013a candidate for chronic systemic delivery of L-Dopa in Parkinson\u2019s disease. Clin Neuropharmacol 7(1):89\u201398","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"1722_CR101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(00)00933-X","volume":"412","author":"S Costa","year":"2001","unstructured":"Costa S, Iravani MM, Pearce RK, Jenner P (2001) Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur J Pharmacol 412(1):45\u201350","journal-title":"Eur J Pharmacol"},{"issue":"3 Suppl","key":"1722_CR102","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1017\/S0317167100037859","volume":"14","author":"AR Crossman","year":"1987","unstructured":"Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA (1987) MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 14(3 Suppl):428\u2013435","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"1722_CR103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.wnr.0000198952.38563.05","volume":"17","author":"MM Daadi","year":"2006","unstructured":"Daadi MM, Pivirotto P, Bringas J, Cunningham J, Forsayeth J, Eberling J, Bankiewicz KS (2006) Distribution of AAV2-hAADC-transduced cells after 3\u00a0years in Parkinsonian monkeys. NeuroReport 17(2):201\u2013204","journal-title":"NeuroReport"},{"issue":"1","key":"1722_CR104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ana.24542","volume":"79","author":"Darlot F, Moro C, El Massri N, Chabrol C, Johnstone DM, Reinhart F, Agay D, Torres N, Bekha D, Auboiroux V, Costecalde T, Peoples CL, Anastascio HD, Shaw VE, Stone J, Mitrofanis J, Benabid AL","year":"2016","unstructured":"Darlot F, Moro C, El Massri N, Chabrol C, Johnstone DM, Reinhart F, Agay D, Torres N, Bekha D, Auboiroux V, Costecalde T, Peoples CL, Anastascio HD, Shaw VE, Stone J, Mitrofanis J, Benabid AL (2016) Near-infrared light is neuroprotective in a monkey model of Parkinson disease. Ann Neurol 79(1):59\u201375. doi: 10.1002\/ana.24542","journal-title":"Ann Neurol"},{"issue":"1","key":"1722_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","volume":"508","author":"SC Daubner","year":"2011","unstructured":"Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508(1):1\u201312. doi: 10.1016\/j.abb.2010.12.017","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"1722_CR106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(79)90006-4","volume":"1","author":"GC Davis","year":"1979","unstructured":"Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1(3):249\u2013254","journal-title":"Psychiatry Res"},{"issue":"5","key":"1722_CR107","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1460-9568.2004.03586.x","volume":"20","author":"E Decamp","year":"2004","unstructured":"Decamp E, Schneider JS (2004) Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 20(5):1371\u20131378. doi: 10.1111\/j.1460-9568.2004.03586.x","journal-title":"Eur J Neurosci"},{"key":"1722_CR108","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.brainres.2009.01.028","volume":"1262","author":"E Decamp","year":"2009","unstructured":"Decamp E, Schneider JS (2009) Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res 1262:109\u2013114. doi: 10.1016\/j.brainres.2009.01.028","journal-title":"Brain Res"},{"issue":"1","key":"1722_CR109","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1152\/jn.90466.2008","volume":"100","author":"C Dejean","year":"2008","unstructured":"Dejean C, Gross CE, Bioulac B, Boraud T (2008) Dynamic changes in the cortex-basal ganglia network after dopamine depletion in the rat. J Neurophysiol 100(1):385\u2013396. doi: 10.1152\/jn.90466.2008","journal-title":"J Neurophysiol"},{"issue":"1","key":"1722_CR110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Tredici Del","year":"2016","unstructured":"Del Tredici K, Braak H (2016) Review: sporadic Parkinson\u2019s disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol 42(1):33\u201350. doi: 10.1111\/nan.12298","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"1722_CR111","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","volume":"13","author":"MR DeLong","year":"1990","unstructured":"DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13(7):281\u2013285","journal-title":"Trends Neurosci"},{"issue":"3","key":"1722_CR112","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3","volume":"15","author":"DA Monte Di","year":"2000","unstructured":"Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 15(3):459\u2013466","journal-title":"Mov Disord"},{"issue":"11","key":"1722_CR113","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.parkreldis.2014.05.007","volume":"20","author":"T Paolo Di","year":"2014","unstructured":"Di Paolo T, Gregoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B (2014) AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 20(11):1119\u20131123. doi: 10.1016\/j.parkreldis.2014.05.007","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"1722_CR114","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I (2009) Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol 8(12):1150\u20131157. doi: 10.1016\/S1474-4422(09)70238-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"1722_CR115","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384\u2013386. doi: 10.1212\/01.wnl.0000247740.47667.03","journal-title":"Neurology"},{"issue":"3","key":"1722_CR116","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ana.24220","volume":"76","author":"LL Dugan","year":"2014","unstructured":"Dugan LL, Tian L, Quick KL, Hardt JI, Karimi M, Brown C, Loftin S, Flores H, Moerlein SM, Polich J, Tabbal SD, Mink JW, Perlmutter JS (2014) Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates. Ann Neurol 76(3):393\u2013402. doi: 10.1002\/ana.24220","journal-title":"Ann Neurol"},{"issue":"8","key":"1722_CR117","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-013-0066-7","volume":"73","author":"R Dungo","year":"2013","unstructured":"Dungo R, Deeks ED (2013) Istradefylline: first global approval. Drugs 73(8):875\u2013882. doi: 10.1007\/s40265-013-0066-7","journal-title":"Drugs"},{"issue":"3","key":"1722_CR118","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ymeth.2009.08.001","volume":"50","author":"TQ Duong","year":"2010","unstructured":"Duong TQ (2010) Diffusion tensor and perfusion MRI of non-human primates. Methods 50(3):125\u2013135. doi: 10.1016\/j.ymeth.2009.08.001","journal-title":"Methods"},{"issue":"4","key":"1722_CR119","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P (2011) Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164(4):1357\u20131391. doi: 10.1111\/j.1476-5381.2011.01426.x","journal-title":"Br J Pharmacol"},{"issue":"21","key":"1722_CR120","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21):1980\u20131983. doi: 10.1212\/01.wnl.0000312381.29287.ff","journal-title":"Neurology"},{"issue":"5","key":"1722_CR121","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/hum.2008.201","volume":"20","author":"JL Eberling","year":"2009","unstructured":"Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS (2009) Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 20(5):511\u2013518. doi: 10.1089\/hum.2008.201","journal-title":"Hum Gene Ther"},{"issue":"11","key":"1722_CR122","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00221-016-4720-7","volume":"234","author":"N Massri El","year":"2016","unstructured":"El Massri N, Moro C, Torres N, Darlot F, Agay D, Chabrol C, Johnstone DM, Stone J, Benabid AL, Mitrofanis J (2016) Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys. Exp Brain Res 234(11):3225\u20133232. doi: 10.1007\/s00221-016-4720-7","journal-title":"Exp Brain Res"},{"issue":"2","key":"1722_CR123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0306-4522(99)00437-6","volume":"95","author":"JD Elsworth","year":"2000","unstructured":"Elsworth JD, Taylor JR, Sladek JR Jr, Collier TJ, Redmond DE Jr, Roth RH (2000) Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95(2):399\u2013408","journal-title":"Neuroscience"},{"issue":"2","key":"1722_CR124","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/(SICI)1096-9861(19981116)401:2<253::AID-CNE7>3.0.CO;2-X","volume":"401","author":"ME Emborg","year":"1998","unstructured":"Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, Holden JE, Kordower JH (1998) Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401(2):253\u2013265","journal-title":"J Comp Neurol"},{"issue":"2","key":"1722_CR125","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.nbd.2006.03.010","volume":"23","author":"ME Emborg","year":"2006","unstructured":"Emborg ME, Moirano J, Schafernak KT, Moirano M, Evans M, Konecny T, Roitberg B, Ambarish P, Mangubat E, Ma Y, Eidelberg D, Holden J, Kordower JH, Leestma JE (2006) Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis 23(2):281\u2013289. doi: 10.1016\/j.nbd.2006.03.010","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1722_CR126","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","volume":"27","author":"ME Emborg","year":"2007","unstructured":"Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, Moirano J, Fitzsimons H, Roitberg BZ, Tuccar E, Roberts A, Kaplitt MG, Eidelberg D (2007) Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27(3):501\u2013509. doi: 10.1038\/sj.jcbfm.9600364","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"1722_CR127","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.celrep.2013.02.016","volume":"3","author":"ME Emborg","year":"2013","unstructured":"Emborg ME, Liu Y, Xi J, Zhang X, Yin Y, Lu J, Joers V, Swanson C, Holden JE, Zhang SC (2013) Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep 3(3):646\u2013650. doi: 10.1016\/j.celrep.2013.02.016","journal-title":"Cell Rep"},{"issue":"9","key":"1722_CR128","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/cercor\/bhu076","volume":"25","author":"M Engeln","year":"2015","unstructured":"Engeln M, De Deurwaerdere P, Li Q, Bezard E, Fernagut PO (2015) Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cereb Cortex 25(9):2783\u20132792. doi: 10.1093\/cercor\/bhu076","journal-title":"Cereb Cortex"},{"issue":"1","key":"1722_CR129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0896-6273(91)90077-D","volume":"7","author":"MG Erlander","year":"1991","unstructured":"Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ (1991) Two genes encode distinct glutamate decarboxylases. Neuron 7(1):91\u2013100","journal-title":"Neuron"},{"issue":"8","key":"1722_CR130","doi-asserted-by":"publisher","first-page":"e70244","DOI":"10.1371\/journal.pone.0070244","volume":"8","author":"R Erro","year":"2013","unstructured":"Erro R, Vitale C, Amboni M, Picillo M, Moccia M, Longo K, Santangelo G, De Rosa A, Allocca R, Giordano F, Orefice G, De Michele G, Santoro L, Pellecchia MT, Barone P (2013) The heterogeneity of early Parkinson\u2019s disease: a cluster analysis on newly diagnosed untreated patients. PLoS ONE 8(8):e70244. doi: 10.1371\/journal.pone.0070244","journal-title":"PLoS ONE"},{"issue":"3","key":"1722_CR131","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.brainresbull.2005.08.005","volume":"68","author":"A Eslamboli","year":"2005","unstructured":"Eslamboli A (2005) Marmoset monkey models of Parkinson\u2019s disease: which model, when and why? Brain Res Bull 68(3):140\u2013149. doi: 10.1016\/j.brainresbull.2005.08.005","journal-title":"Brain Res Bull"},{"issue":"2","key":"1722_CR132","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0014-4886(03)00139-0","volume":"183","author":"A Eslamboli","year":"2003","unstructured":"Eslamboli A, Baker HF, Ridley RM, Annett LE (2003a) Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson\u2019s disease in marmoset monkeys. Exp Neurol 183(2):418\u2013429","journal-title":"Exp Neurol"},{"issue":"1","key":"1722_CR133","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.expneurol.2003.08.007","volume":"184","author":"A Eslamboli","year":"2003","unstructured":"Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Kirik D, Annett LE (2003b) Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol 184(1):536\u2013548","journal-title":"Exp Neurol"},{"issue":"4","key":"1722_CR134","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1523\/JNEUROSCI.4421-04.2005","volume":"25","author":"A Eslamboli","year":"2005","unstructured":"Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D (2005) Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson\u2019s disease. J Neurosci 25(4):769\u2013777. doi: 10.1523\/JNEUROSCI.4421-04.2005","journal-title":"J Neurosci"},{"issue":"Pt 3","key":"1722_CR135","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/brain\/awl382","volume":"130","author":"A Eslamboli","year":"2007","unstructured":"Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130(Pt 3):799\u2013815. doi: 10.1093\/brain\/awl382","journal-title":"Brain"},{"issue":"5","key":"1722_CR136","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2012.01.020","volume":"18","author":"AH Evans","year":"2012","unstructured":"Evans AH, Farrell MJ, Gibson SJ, Helme RD, Lim SY (2012) Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge. Parkinsonism Relat Disord 18(5):514\u2013519. doi: 10.1016\/j.parkreldis.2012.01.020","journal-title":"Parkinsonism Relat Disord"},{"key":"1722_CR137","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.02.021","volume":"26","author":"M Fabbri","year":"2016","unstructured":"Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Costa N, Antonini A, Ferreira JJ (2016) Do patients with late-stage Parkinson\u2019s disease still respond to levodopa? Parkinsonism Relat Disord 26:10\u201316. doi: 10.1016\/j.parkreldis.2016.02.021","journal-title":"Parkinsonism Relat Disord"},{"key":"1722_CR138","doi-asserted-by":"publisher","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22 (10):1379-1389; quiz 1523. doi: 10.1002\/mds.21475","DOI":"10.1002\/mds.21475"},{"issue":"1\u20132","key":"1722_CR139","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(88)90750-9","volume":"150","author":"P Falardeau","year":"1988","unstructured":"Falardeau P, Bouchard S, Bedard PJ, Boucher R, Di Paolo T (1988) Behavioral and biochemical effect of chronic treatment with D-1 and\/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 150(1\u20132):59\u201366","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1722_CR140","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/1531-8257(199909)14:5<836::AID-MDS1018>3.0.CO;2-0","volume":"14","author":"HH Fernandez","year":"1999","unstructured":"Fernandez HH, Friedman JH (1999) Punding on L-dopa. Mov Disord 14(5):836\u2013838","journal-title":"Mov Disord"},{"key":"1722_CR141","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.expneurol.2013.03.014","volume":"256","author":"MS Fiandaca","year":"2014","unstructured":"Fiandaca MS, Federoff HJ (2014) Using viral-mediated gene delivery to model Parkinson\u2019s disease: do nonhuman primate investigations expand our understanding? Exp Neurol 256:117\u2013125. doi: 10.1016\/j.expneurol.2013.03.014","journal-title":"Exp Neurol"},{"issue":"1","key":"1722_CR142","doi-asserted-by":"publisher","first-page":"e86240","DOI":"10.1371\/journal.pone.0086240","volume":"9","author":"K Fifel","year":"2014","unstructured":"Fifel K, Vezoli J, Dzahini K, Claustrat B, Leviel V, Kennedy H, Procyk E, Dkhissi-Benyahya O, Gronfier C, Cooper HM (2014) Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates. PLoS ONE 9(1):e86240. doi: 10.1371\/journal.pone.0086240","journal-title":"PLoS ONE"},{"issue":"1","key":"1722_CR143","first-page":"142","volume":"547","author":"M Filion","year":"1991","unstructured":"Filion M, Tremblay L (1991) Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547(1):142\u2013151","journal-title":"Brain Res"},{"issue":"22","key":"1722_CR144","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ, Jr., Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ, Group CSPS","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ, Jr., Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ, Group CSPS (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 362(22):2077\u20132091. doi: 10.1056\/NEJMoa0907083","journal-title":"N Engl J Med"},{"issue":"4","key":"1722_CR145","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ana.410200403","volume":"20","author":"LS Forno","year":"1986","unstructured":"Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20(4):449\u2013455. doi: 10.1002\/ana.410200403","journal-title":"Ann Neurol"},{"issue":"4","key":"1722_CR146","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2006.04.008","volume":"14","author":"JR Forsayeth","year":"2006","unstructured":"Forsayeth JR, Eberling JL, Sanftner LM, Zhen Z, Pivirotto P, Bringas J, Cunningham J, Bankiewicz KS (2006) A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 14(4):571\u2013577. doi: 10.1016\/j.ymthe.2006.04.008","journal-title":"Mol Ther"},{"issue":"13","key":"1722_CR147","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","volume":"73","author":"SH Fox","year":"2013","unstructured":"Fox SH (2013) Non-dopaminergic treatments for motor control in Parkinson\u2019s disease. Drugs 73(13):1405\u20131415. doi: 10.1007\/s40265-013-0105-4","journal-title":"Drugs"},{"key":"1722_CR148","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0079-6123(10)84007-5","volume":"184","author":"SH Fox","year":"2010","unstructured":"Fox SH, Brotchie JM (2010) The MPTP-lesioned non-human primate models of Parkinson\u2019s disease. Past, present, and future. Prog Brain Res 184:133\u2013157. doi: 10.1016\/S0079-6123(10)84007-5","journal-title":"Prog Brain Res"},{"issue":"10","key":"1722_CR149","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/mds.20936","volume":"21","author":"SH Fox","year":"2006","unstructured":"Fox SH, Lang AE, Brotchie JM (2006) Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord 21(10):1578\u20131594. doi: 10.1002\/mds.20936","journal-title":"Mov Disord"},{"issue":"10","key":"1722_CR150","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","volume":"7","author":"SH Fox","year":"2008","unstructured":"Fox SH, Brotchie JM, Lang AE (2008) Non-dopaminergic treatments in development for Parkinson\u2019s disease. Lancet Neurol 7(10):927\u2013938. doi: 10.1016\/S1474-4422(08)70214-X","journal-title":"Lancet Neurol"},{"issue":"1","key":"1722_CR151","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","volume":"37","author":"SH Fox","year":"2010","unstructured":"Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson\u2019s disease. Can J Neurol Sci 37(1):86\u201395","journal-title":"Can J Neurol Sci"},{"issue":"Suppl 3","key":"1722_CR152","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/mds.23829","volume":"26","author":"SH Fox","year":"2011","unstructured":"Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 26(Suppl 3):S2\u201341. doi: 10.1002\/mds.23829","journal-title":"Mov Disord"},{"issue":"11","key":"1722_CR153","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/mds.25133","volume":"27","author":"SH Fox","year":"2012","unstructured":"Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E (2012) A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov Disord 27(11):1373\u20131378. doi: 10.1002\/mds.25133","journal-title":"Mov Disord"},{"issue":"Pt 6","key":"1722_CR154","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/brain\/awm090","volume":"130","author":"R Fronczek","year":"2007","unstructured":"Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin) loss in Parkinson\u2019s disease. Brain 130(Pt 6):1577\u20131585. doi: 10.1093\/brain\/awm090","journal-title":"Brain"},{"issue":"1","key":"1722_CR155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0091-3057(00)00305-1","volume":"67","author":"K Fukuzaki","year":"2000","unstructured":"Fukuzaki K, Kamenosono T, Kitazumi K, Nagata R (2000) Effects of ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol Biochem Behav 67(1):121\u2013129","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"1722_CR156","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/mds.23499","volume":"26","author":"A Gaenslen","year":"2011","unstructured":"Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients\u2019 perception of prodromal symptoms before the initial diagnosis of Parkinson\u2019s disease. Mov Disord 26(4):653\u2013658. doi: 10.1002\/mds.23499","journal-title":"Mov Disord"},{"issue":"1","key":"1722_CR157","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94802-5","volume":"178","author":"C Gagnon","year":"1990","unstructured":"Gagnon C, Bedard PJ, Di Paolo T (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and\/or D-2 receptor agonists. Eur J Pharmacol 178(1):115\u2013120","journal-title":"Eur J Pharmacol"},{"key":"1722_CR158","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.biomaterials.2016.09.015","volume":"110","author":"E Garbayo","year":"2016","unstructured":"Garbayo E, Ansorena E, Lana H, Carmona-Abellan MD, Marcilla I, Lanciego JL, Luquin MR, Blanco-Prieto MJ (2016) Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys. Biomaterials 110:11\u201323. doi: 10.1016\/j.biomaterials.2016.09.015","journal-title":"Biomaterials"},{"issue":"10","key":"1722_CR159","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1093\/cercor\/bhp317","volume":"20","author":"BG Garcia","year":"2010","unstructured":"Garcia BG, Neely MD, Deutch AY (2010) Cortical Regulation of Striatal Medium Spiny Neuron Dendritic Remodeling in Parkinsonism: modulation of Glutamate Release Reverses Dopamine Depletion-Induced Dendritic Spine Loss. Cereb Cortex 20(10):2423\u20132432","journal-title":"Cereb Cortex"},{"issue":"6571","key":"1722_CR160","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/380252a0","volume":"380","author":"DM Gash","year":"1996","unstructured":"Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380(6571):252\u2013255. doi: 10.1038\/380252a0","journal-title":"Nature"},{"issue":"2","key":"1722_CR161","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ana.20549","volume":"58","author":"DM Gash","year":"2005","unstructured":"Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt GA (2005) Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 58(2):224\u2013233. doi: 10.1002\/ana.20549","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"1722_CR162","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0006-8993(98)01244-X","volume":"817","author":"GA Gerhardt","year":"1999","unstructured":"Gerhardt GA, Cass WA, Huettl P, Brock S, Zhang Z, Gash DM (1999) GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 817(1\u20132):163\u2013171","journal-title":"Brain Res"},{"issue":"6","key":"1722_CR163","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","volume":"24","author":"M Gesi","year":"2000","unstructured":"Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F (2000) The role of the locus coeruleus in the development of Parkinson\u2019s disease. Neurosci Biobehav Rev 24(6):655\u2013668","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"1722_CR164","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR, O\u2019Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9(5):589\u2013595. doi: 10.1038\/nm850","journal-title":"Nat Med"},{"issue":"3","key":"1722_CR165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF02246102","volume":"117","author":"KK Gnanalingham","year":"1995","unstructured":"Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD (1995a) Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117(3):275\u2013286","journal-title":"Psychopharmacology"},{"issue":"3","key":"1722_CR166","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF02246103","volume":"117","author":"KK Gnanalingham","year":"1995","unstructured":"Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995b) The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson\u2019s disease. Psychopharmacology 117(3):287\u2013297","journal-title":"Psychopharmacology"},{"issue":"4","key":"1722_CR167","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00002826-198212000-00003","volume":"5","author":"CG Goetz","year":"1982","unstructured":"Goetz CG, Tanner CM, Klawans HL (1982) Drug holiday in the management of Parkinson disease. Clin Neuropharmacol 5(4):351\u2013364","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"1722_CR168","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mds.21897","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Laska E, Hicking C, Damier P, Muller T, Nutt J, Warren Olanow C, Rascol O, Russ H (2008) Placebo influences on dyskinesia in Parkinson\u2019s disease. Mov Disord 23(5):700\u2013707. doi: 10.1002\/mds.21897","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR169","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1124\/jpet.103.051714","volume":"306","author":"DS Goldstein","year":"2003","unstructured":"Goldstein DS, Li ST, Holmes C, Bankiewicz K (2003) Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson\u2019s disease. J Pharmacol Exp Ther 306(3):855\u2013860. doi: 10.1124\/jpet.103.051714","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1722_CR170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0014-4886(92)90125-A","volume":"117","author":"B Gomez-Mancilla","year":"1992","unstructured":"Gomez-Mancilla B, Bedard PJ (1992) Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 117(2):185\u2013188","journal-title":"Exp Neurol"},{"issue":"2","key":"1722_CR171","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0006-8993(93)90694-I","volume":"602","author":"WC Graham","year":"1993","unstructured":"Graham WC, Sambrook MA, Crossman AR (1993) Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 602(2):290\u2013303","journal-title":"Brain Res"},{"issue":"10 Suppl","key":"1722_CR172","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S1471-1931(00)00027-6","volume":"23","author":"AM Graybiel","year":"2000","unstructured":"Graybiel AM, Canales JJ, Capper-Loup C (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 23(10 Suppl):S71\u201377","journal-title":"Trends Neurosci"},{"issue":"2","key":"1722_CR173","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","volume":"186","author":"L Gregoire","year":"2008","unstructured":"Gregoire L, Rassoulpour A, Guidetti P, Samadi P, Bedard PJ, Izzo E, Schwarcz R, Di Paolo T (2008) Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 186(2):161\u2013167. doi: 10.1016\/j.bbr.2007.08.007","journal-title":"Behav Brain Res"},{"issue":"6","key":"1722_CR174","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","volume":"15","author":"L Gregoire","year":"2009","unstructured":"Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 15(6):445\u2013452. doi: 10.1016\/j.parkreldis.2008.11.001","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1722_CR175","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","volume":"17","author":"L Gregoire","year":"2011","unstructured":"Gregoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17(4):270\u2013276. doi: 10.1016\/j.parkreldis.2011.01.008","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1722_CR176","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","volume":"19","author":"L Gregoire","year":"2013","unstructured":"Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T (2013) Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 19(5):508\u2013514. doi: 10.1016\/j.parkreldis.2013.01.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1722_CR177","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0006-8993(96)00597-5","volume":"735","author":"R Grondin","year":"1996","unstructured":"Grondin R, Goulet M, Di Paolo T, Bedard PJ (1996) Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 735(2):298\u2013306","journal-title":"Brain Res"},{"issue":"Pt 10","key":"1722_CR178","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","volume":"125","author":"R Grondin","year":"2002","unstructured":"Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, Elsberry DD, Klein MC, Gerhardt GA, Gash DM (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125(Pt 10):2191\u20132201","journal-title":"Brain"},{"issue":"5","key":"1722_CR179","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1523\/JNEUROSCI.23-05-01974.2003","volume":"23","author":"R Grondin","year":"2003","unstructured":"Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, Gerhardt GA (2003) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 23(5):1974\u20131980","journal-title":"J Neurosci"},{"issue":"4","key":"1722_CR180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3727\/096368908784423256","volume":"17","author":"R Grondin","year":"2008","unstructured":"Grondin R, Zhang Z, Ai Y, Ding F, Walton AA, Surgener SP, Gerhardt GA, Gash DM (2008) Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant 17(4):373\u2013381","journal-title":"Cell Transplant"},{"key":"1722_CR181","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fncel.2016.00293","volume":"10","author":"J Grosch","year":"2016","unstructured":"Grosch J, Winkler J, Kohl Z (2016) Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson\u2019s Disease. Front Cell Neurosci 10:293. doi: 10.3389\/fncel.2016.00293","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"1722_CR182","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.scr.2016.08.013","volume":"17","author":"DA Grow","year":"2016","unstructured":"Grow DA, McCarrey JR, Navara CS (2016) Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson\u2019s disease. Stem Cell Res 17(2):352\u2013366. doi: 10.1016\/j.scr.2016.08.013","journal-title":"Stem Cell Res"},{"issue":"1","key":"1722_CR183","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1460-9568.2005.04196.x","volume":"22","author":"C Guigoni","year":"2005","unstructured":"Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, Gurevich EV, Gross CE, Bezard E (2005) Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 22(1):283\u2013287. doi: 10.1111\/j.1460-9568.2005.04196.x","journal-title":"Eur J Neurosci"},{"issue":"5","key":"1722_CR184","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/ana.410190510","volume":"19","author":"M Guttman","year":"1986","unstructured":"Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D2 receptor density remains constant in treated Parkinson\u2019s disease. Ann Neurol 19(5):487\u2013492. doi: 10.1002\/ana.410190510","journal-title":"Ann Neurol"},{"issue":"4","key":"1722_CR185","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.stem.2009.08.021","volume":"5","author":"A Haase","year":"2009","unstructured":"Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, Zweigerdt R, Gruh I, Meyer J, Wagner S, Maier LS, Han DW, Glage S, Miller K, Fischer P, Scholer HR, Martin U (2009) Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5(4):434\u2013441. doi: 10.1016\/j.stem.2009.08.021","journal-title":"Cell Stem Cell"},{"issue":"8","key":"1722_CR186","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/mt.2010.106","volume":"18","author":"P Hadaczek","year":"2010","unstructured":"Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18(8):1458\u20131461. doi: 10.1038\/mt.2010.106","journal-title":"Mol Ther"},{"issue":"4","key":"1722_CR187","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-200007000-00005","volume":"23","author":"A Hadj Tahar","year":"2000","unstructured":"Hadj Tahar A, Gregoire L, Bangassoro E, Bedard PJ (2000) Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 23(4):195\u2013202","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1722_CR188","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","volume":"15","author":"A Hadj Tahar","year":"2004","unstructured":"Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ (2004) Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 15(2):171\u2013176. doi: 10.1016\/j.nbd.2003.10.007","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1722_CR189","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1755-5949.2008.00058.x","volume":"14","author":"M Hadjiconstantinou","year":"2008","unstructured":"Hadjiconstantinou M, Neff NH (2008) Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson\u2019s disease. CNS Neurosci Ther 14(4):340\u2013351. doi: 10.1111\/j.1755-5949.2008.00058.x","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"1722_CR190","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","volume":"16","author":"PJ Hallett","year":"2015","unstructured":"Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O (2015) Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson\u2019s disease. Cell Stem Cell 16(3):269\u2013274. doi: 10.1016\/j.stem.2015.01.018","journal-title":"Cell Stem Cell"},{"issue":"Suppl 3","key":"1722_CR191","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/S1353-8020(09)70804-1","volume":"15","author":"GM Halliday","year":"2009","unstructured":"Halliday GM (2009) Thalamic changes in Parkinson\u2019s disease. Parkinsonism Relat Disord 15(Suppl 3):S152\u2013155. doi: 10.1016\/S1353-8020(09)70804-1","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1722_CR192","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease. Brain Res 510(1):104\u2013107","journal-title":"Brain Res"},{"issue":"10","key":"1722_CR193","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/mds.22481","volume":"24","author":"G Halliday","year":"2009","unstructured":"Halliday G, Herrero MT, Murphy K, McCann H, Ros-Bernal F, Barcia C, Mori H, Blesa FJ, Obeso JA (2009) No Lewy pathology in monkeys with over 10\u00a0years of severe MPTP Parkinsonism. Mov Disord 24(10):1519\u20131523. doi: 10.1002\/mds.22481","journal-title":"Mov Disord"},{"issue":"Pt 1","key":"1722_CR194","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/brain\/awh029","volume":"127","author":"C Hamani","year":"2004","unstructured":"Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM (2004) The subthalamic nucleus in the context of movement disorders. Brain 127(Pt 1):4\u201320. doi: 10.1093\/brain\/awh029","journal-title":"Brain"},{"key":"1722_CR195","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbacli.2016.09.002","volume":"6","author":"MR Hamblin","year":"2016","unstructured":"Hamblin MR (2016) Shining light on the head: photobiomodulation for brain disorders. BBA Clin 6:113\u2013124. doi: 10.1016\/j.bbacli.2016.09.002","journal-title":"BBA Clin"},{"issue":"2","key":"1722_CR196","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(02)02268-9","volume":"451","author":"MJ Hansard","year":"2002","unstructured":"Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (2002a) Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol 451(2):157\u2013160","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1722_CR197","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1124\/jpet.102.039743","volume":"303","author":"MJ Hansard","year":"2002","unstructured":"Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (2002b) Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 303(3):952\u2013958. doi: 10.1124\/jpet.102.039743","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1722_CR198","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mds.10596","volume":"19","author":"MJ Hansard","year":"2004","unstructured":"Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (2004) The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Mov Disord 19(1):15\u201321. doi: 10.1002\/mds.10596","journal-title":"Mov Disord"},{"issue":"1","key":"1722_CR199","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0306-4522(93)90295-Q","volume":"53","author":"P Hantraye","year":"1993","unstructured":"Hantraye P, Varastet M, Peschanski M, Riche D, Cesaro P, Willer JC, Maziere M (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53(1):169\u2013178","journal-title":"Neuroscience"},{"issue":"3","key":"1722_CR200","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nrn3253","volume":"14","author":"AW Harrington","year":"2013","unstructured":"Harrington AW, Ginty DD (2013) Long-distance retrograde neurotrophic factor signalling in neurons. Nat Rev Neurosci 14(3):177\u2013187. doi: 10.1038\/nrn3253","journal-title":"Nat Rev Neurosci"},{"issue":"50","key":"1722_CR201","doi-asserted-by":"publisher","first-page":"49071","DOI":"10.1074\/jbc.M208046200","volume":"277","author":"M Hasegawa","year":"2002","unstructured":"Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 277(50):49071\u201349076. doi: 10.1074\/jbc.M208046200","journal-title":"J Biol Chem"},{"issue":"3","key":"1722_CR202","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.21258","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Salin L, Juhel N, Konyago VL (2007) Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson\u2019s disease. Mov Disord 22(3):359\u2013365. doi: 10.1002\/mds.21258","journal-title":"Mov Disord"},{"key":"1722_CR203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-211-45295-0_4","volume":"70","author":"G Heimer","year":"2006","unstructured":"Heimer G, Rivlin M, Israel Z, Bergman H (2006) Synchronizing activity of basal ganglia and pathophysiology of Parkinson\u2019s disease. J Neural Transm Suppl 70:17\u201320","journal-title":"J Neural Transm Suppl"},{"issue":"3","key":"1722_CR204","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/1531-8249(200003)47:3<345::AID-ANA10>3.0.CO;2-V","volume":"47","author":"JM Henderson","year":"2000","unstructured":"Henderson JM, Carpenter K, Cartwright H, Halliday GM (2000) Degeneration of the centre median-parafascicular complex in Parkinson\u2019s disease. Ann Neurol 47(3):345\u2013352","journal-title":"Ann Neurol"},{"issue":"8","key":"1722_CR205","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/mds.21503","volume":"22","author":"CD Herzog","year":"2007","unstructured":"Herzog CD, Dass B, Holden JE, Stansell J 3rd, Gasmi M, Tuszynski MH, Bartus RT, Kordower JH (2007) Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22(8):1124\u20131132. doi: 10.1002\/mds.21503","journal-title":"Mov Disord"},{"issue":"10","key":"1722_CR206","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/mt.2008.170","volume":"16","author":"CD Herzog","year":"2008","unstructured":"Herzog CD, Dass B, Gasmi M, Bakay R, Stansell JE, Tuszynski M, Bankiewicz K, Chen EY, Chu Y, Bishop K, Kordower JH, Bartus RT (2008) Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther 16(10):1737\u20131744. doi: 10.1038\/mt.2008.170","journal-title":"Mol Ther"},{"key":"1722_CR207","doi-asserted-by":"publisher","unstructured":"Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT (2009) Expression, bioactivity, and safety 1\u00a0year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson\u2019s disease. Neurosurgery 64 (4):602-612; discussion 612-603. doi: 10.1227\/01.NEU.0000340682.06068.01","DOI":"10.1227\/01.NEU.0000340682.06068.01"},{"issue":"1","key":"1722_CR208","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/14712598.2013.754420","volume":"13","author":"P Hickey","year":"2013","unstructured":"Hickey P, Stacy M (2013) AAV2-neurturin (CERE-120) for Parkinson\u2019s disease. Expert Opin Biol Ther 13(1):137\u2013145. doi: 10.1517\/14712598.2013.754420","journal-title":"Expert Opin Biol Ther"},{"key":"1722_CR209","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fnins.2016.00173","volume":"10","author":"P Hickey","year":"2016","unstructured":"Hickey P, Stacy M (2016) Deep Brain Stimulation: a Paradigm Shifting Approach to Treat Parkinson\u2019s Disease. Front Neurosci 10:173. doi: 10.3389\/fnins.2016.00173","journal-title":"Front Neurosci"},{"issue":"16","key":"1722_CR210","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1073\/pnas.84.16.5976","volume":"84","author":"EC Hirsch","year":"1987","unstructured":"Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 84(16):5976\u20135980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1722_CR211","first-page":"13","volume":"3","author":"O Hornykiewicz","year":"1975","unstructured":"Hornykiewicz O (1975) Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 3:13\u201321","journal-title":"Natl Inst Drug Abuse Res Monogr Ser"},{"issue":"2","key":"1722_CR212","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","volume":"95","author":"P Huot","year":"2011","unstructured":"Huot P, Fox SH, Brotchie JM (2011) The serotonergic system in Parkinson\u2019s disease. Prog Neurobiol 95(2):163\u2013212. doi: 10.1016\/j.pneurobio.2011.08.004","journal-title":"Prog Neurobiol"},{"issue":"5","key":"1722_CR213","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","volume":"63","author":"P Huot","year":"2012","unstructured":"Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2012a) L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson\u2019s disease. Neuropharmacology 63(5):829\u2013836. doi: 10.1016\/j.neuropharm.2012.06.012","journal-title":"Neuropharmacology"},{"key":"1722_CR214","doi-asserted-by":"publisher","unstructured":"Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM (2012b) 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiol Aging 33 (1):194 e195-115. doi: 10.1016\/j.neurobiolaging.2010.04.035","DOI":"10.1016\/j.neurobiolaging.2010.04.035"},{"key":"1722_CR215","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuropharm.2015.05.033","volume":"97","author":"P Huot","year":"2015","unstructured":"Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM (2015) The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology 97:306\u2013311. doi: 10.1016\/j.neuropharm.2015.05.033","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"1722_CR216","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0304-3940(96)12884-6","volume":"214","author":"MJ Hurley","year":"1996","unstructured":"Hurley MJ, Stubbs CM, Jenner P, Marsden CD (1996) D3 receptor expression within the basal ganglia is not affected by Parkinson\u2019s disease. Neurosci Lett 214(2\u20133):75\u201378","journal-title":"Neurosci Lett"},{"key":"1722_CR217","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuroscience.2012.03.023","volume":"211","author":"H Iderberg","year":"2012","unstructured":"Iderberg H, Francardo V, Pioli EY (2012) Animal models of L-DOPA-induced dyskinesia: an update on the current options. Neuroscience 211:13\u201327. doi: 10.1016\/j.neuroscience.2012.03.023","journal-title":"Neuroscience"},{"key":"1722_CR218","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1756-6606-5-35","volume":"5","author":"Y Imaizumi","year":"2012","unstructured":"Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H (2012) Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 5:35. doi: 10.1186\/1756-6606-5-35","journal-title":"Mol Brain"},{"issue":"1","key":"1722_CR219","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(99)00184-3","volume":"96","author":"C Imbert","year":"2000","unstructured":"Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE (2000) Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 96(1):71\u201376","journal-title":"J Neurosci Methods"},{"issue":"6","key":"1722_CR220","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/j.1460-9568.2005.04308.x","volume":"22","author":"MM Iravani","year":"2005","unstructured":"Iravani MM, Costa S, Al-Bargouthy G, Jackson MJ, Zeng BY, Kuoppamaki M, Obeso JA, Jenner P (2005) Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. Eur J Neurosci 22(6):1305\u20131318. doi: 10.1111\/j.1460-9568.2005.04308.x","journal-title":"Eur J Neurosci"},{"issue":"2","key":"1722_CR221","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/jb\/mvw037","volume":"160","author":"K Ito","year":"2016","unstructured":"Ito K, Enomoto H (2016) Retrograde transport of neurotrophic factor signaling: implications in neuronal development and pathogenesis. J Biochem 160(2):77\u201385. doi: 10.1093\/jb\/mvw037","journal-title":"J Biochem"},{"issue":"3","key":"1722_CR222","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.neuron.2015.03.021","volume":"86","author":"JC Izpisua Belmonte","year":"2015","unstructured":"Izpisua Belmonte JC, Callaway EM, Caddick SJ, Churchland P, Feng G, Homanics GE, Lee KF, Leopold DA, Miller CT, Mitchell JF, Mitalipov S, Moutri AR, Movshon JA, Okano H, Reynolds JH, Ringach D, Sejnowski TJ, Silva AC, Strick PL, Wu J, Zhang F (2015) Brains, genes, and primates. Neuron 86(3):617\u2013631. doi: 10.1016\/j.neuron.2015.03.021","journal-title":"Neuron"},{"issue":"1","key":"1722_CR223","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","volume":"204","author":"MJ Jackson","year":"2007","unstructured":"Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P (2007) Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 204(1):162\u2013170. doi: 10.1016\/j.expneurol.2006.10.005","journal-title":"Exp Neurol"},{"key":"1722_CR224","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3389\/fnins.2015.00503","volume":"9","author":"SA Jagmag","year":"2016","unstructured":"Jagmag SA, Tripathi N, Shukla SD, Maiti S, Khurana S (2016) Evaluation of Models of Parkinson\u2019s Disease. Front Neurosci 9:503. doi: 10.3389\/fnins.2015.00503","journal-title":"Front Neurosci"},{"issue":"4","key":"1722_CR225","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1353-8020(01)00040-2","volume":"8","author":"J Jankovic","year":"2002","unstructured":"Jankovic J, Hunter C (2002) A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson\u2019s disease. Parkinsonism Relat Disord 8(4):271\u2013276","journal-title":"Parkinsonism Relat Disord"},{"key":"1722_CR226","doi-asserted-by":"publisher","unstructured":"Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Herard AS, Day DM, Brouillet E, Kingsman SM, Hantraye P, Mitrophanous KA, Mazarakis ND, Palfi S (2009) Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1 (2):2ra4. doi: 10.1126\/scitranslmed.3000130","DOI":"10.1126\/scitranslmed.3000130"},{"key":"1722_CR227","first-page":"1","volume":"45","author":"K Jellinger","year":"1987","unstructured":"Jellinger K (1987) Overview of morphological changes in Parkinson\u2019s disease. Adv Neurol 45:1\u201318","journal-title":"Adv Neurol"},{"issue":"4","key":"1722_CR228","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp.51.4.540","volume":"51","author":"K Jellinger","year":"1988","unstructured":"Jellinger K (1988) The pedunculopontine nucleus in Parkinson\u2019s disease, progressive supranuclear palsy and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 51(4):540\u2013543","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1722_CR229","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mds.23795","volume":"27","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA (2012) Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts. Mov Disord 27(1):8\u201330. doi: 10.1002\/mds.23795","journal-title":"Mov Disord"},{"issue":"10","key":"1722_CR230","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00702-015-1405-5","volume":"122","author":"KA Jellinger","year":"2015","unstructured":"Jellinger KA (2015) Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) 122(10):1429\u20131440. doi: 10.1007\/s00702-015-1405-5","journal-title":"J Neural Transm (Vienna)"},{"key":"1722_CR231","unstructured":"Jenner P (2002) Experimental models of Parkinson\u2019s disease. In: Ronken E, Scharrenburg v (eds) Parkinson\u2019s disease. IOS Press, London, pp 39-50"},{"issue":"3","key":"1722_CR232","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1353-8020(02)00115-3","volume":"9","author":"P Jenner","year":"2003","unstructured":"Jenner P (2003a) The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson\u2019s disease. Parkinsonism Relat Disord 9(3):131\u2013137","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 1","key":"1722_CR233","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00019052-200312001-00002","volume":"16","author":"P Jenner","year":"2003","unstructured":"Jenner P (2003b) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson\u2019s disease. Curr Opin Neurol 16(Suppl 1):S3\u20137","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 2","key":"1722_CR234","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1331.2008.02211.x","volume":"15","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008a) Dopamine agonists in Parkinson\u2019s disease\u2013focus on non-motor symptoms. Eur J Neurol 15(Suppl 2):1. doi: 10.1111\/j.1468-1331.2008.02211.x","journal-title":"Eur J Neurol"},{"issue":"Suppl 2","key":"1722_CR235","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/ana.21489","volume":"64","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008b) Functional models of Parkinson\u2019s disease: a valuable tool in the development of novel therapies. Ann Neurol 64(Suppl 2):S16\u201329. doi: 10.1002\/ana.21489","journal-title":"Ann Neurol"},{"issue":"9","key":"1722_CR236","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008c) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665\u2013677. doi: 10.1038\/nrn2471","journal-title":"Nat Rev Neurosci"},{"issue":"1\u20133","key":"1722_CR237","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","volume":"50","author":"P Jenner","year":"1984","unstructured":"Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50(1\u20133):85\u201390","journal-title":"Neurosci Lett"},{"issue":"9","key":"1722_CR238","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/nn.4362","volume":"19","author":"CG Jennings","year":"2016","unstructured":"Jennings CG, Landman R, Zhou Y, Sharma J, Hyman J, Movshon JA, Qiu Z, Roberts AC, Roe AW, Wang X, Zhou H, Wang L, Zhang F, Desimone R, Feng G (2016) Opportunities and challenges in modeling human brain disorders in transgenic primates. Nat Neurosci 19(9):1123\u20131130. doi: 10.1038\/nn.4362","journal-title":"Nat Neurosci"},{"issue":"8","key":"1722_CR239","doi-asserted-by":"publisher","first-page":"e104850","DOI":"10.1371\/journal.pone.0104850","volume":"9","author":"V Joers","year":"2014","unstructured":"Joers V, Dilley K, Rahman S, Jones C, Shultz J, Simmons H, Emborg ME (2014) Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates. PLoS ONE 9(8):e104850. doi: 10.1371\/journal.pone.0104850","journal-title":"PLoS ONE"},{"issue":"7","key":"1722_CR240","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1152\/jn.00997.2014","volume":"113","author":"LA Johnson","year":"2015","unstructured":"Johnson LA, Xu W, Baker KB, Zhang J, Vitek JL (2015) Modulation of motor cortex neuronal activity and motor behavior during subthalamic nucleus stimulation in the normal primate. J Neurophysiol 113(7):2549\u20132554. doi: 10.1152\/jn.00997.2014","journal-title":"J Neurophysiol"},{"key":"1722_CR241","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2014_352","volume":"22","author":"TM Johnston","year":"2015","unstructured":"Johnston TM, Fox SH (2015) Symptomatic Models of Parkinson\u2019s Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. Curr Top Behav Neurosci 22:221\u2013235. doi: 10.1007\/7854_2014_352","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"1722_CR242","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/hum.2008.137","volume":"20","author":"LC Johnston","year":"2009","unstructured":"Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J, Bankiewicz KS (2009) Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20(5):497\u2013510. doi: 10.1089\/hum.2008.137","journal-title":"Hum Gene Ther"},{"issue":"3","key":"1722_CR243","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1124\/jpet.110.166629","volume":"333","author":"TH Johnston","year":"2010","unstructured":"Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM (2010) Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease. J Pharmacol Exp Ther 333(3):865\u2013873. doi: 10.1124\/jpet.110.166629","journal-title":"J Pharmacol Exp Ther"},{"key":"1722_CR244","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","volume":"73","author":"TH Johnston","year":"2013","unstructured":"Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM (2013) TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73:337\u2013347. doi: 10.1016\/j.neuropharm.2013.06.005","journal-title":"Neuropharmacology"},{"key":"1722_CR245","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fnins.2015.00500","volume":"9","author":"DM Johnstone","year":"2015","unstructured":"Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J (2015) Turning On Lights to Stop Neurodegeneration: the Potential of Near Infrared Light Therapy in Alzheimer\u2019s and Parkinson\u2019s Disease. Front Neurosci 9:500. doi: 10.3389\/fnins.2015.00500","journal-title":"Front Neurosci"},{"issue":"1","key":"1722_CR246","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3171\/2012.9.JNS12295","volume":"118","author":"VA Jourdain","year":"2013","unstructured":"Jourdain VA, Gregoire L, Morissette M, Morin N, Parent M, Di Paolo T (2013) Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy. J Neurosurg 118(1):180\u2013191. doi: 10.3171\/2012.9.JNS12295","journal-title":"J Neurosurg"},{"issue":"9996","key":"1722_CR247","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912. doi: 10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"issue":"2","key":"1722_CR248","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrneurol.2015.249","volume":"12","author":"LV Kalia","year":"2016","unstructured":"Kalia LV, Lang AE (2016) Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD. Nat Rev Neurol 12(2):65\u201366. doi: 10.1038\/nrneurol.2015.249","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1722_CR249","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/mds.26354","volume":"30","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Kalia SK, Lang AE (2015) Disease-modifying strategies for Parkinson\u2019s disease. Mov Disord 30(11):1442\u20131450. doi: 10.1002\/mds.26354","journal-title":"Mov Disord"},{"issue":"5","key":"1722_CR250","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","volume":"134","author":"K Kalinderi","year":"2016","unstructured":"Kalinderi K, Bostantjopoulou S, Fidani L (2016) The genetic background of Parkinson\u2019s disease: current progress and future prospects. Acta Neurol Scand 134(5):314\u2013326. doi: 10.1111\/ane.12563","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1722_CR251","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JPD-012138","volume":"2","author":"NM Kanaan","year":"2012","unstructured":"Kanaan NM, Manfredsson FP (2012) Loss of functional alpha-synuclein: a toxic event in Parkinson\u2019s disease? J Parkinsons Dis 2(4):249\u2013267. doi: 10.3233\/JPD-012138","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"1722_CR252","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/exnr.2000.7350","volume":"162","author":"T Kanda","year":"2000","unstructured":"Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162(2):321\u2013327. doi: 10.1006\/exnr.2000.7350","journal-title":"Exp Neurol"},{"issue":"9579","key":"1722_CR253","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369(9579):2097\u20132105. doi: 10.1016\/S0140-6736(07)60982-9","journal-title":"Lancet"},{"issue":"7","key":"1722_CR254","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","volume":"71","author":"Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson\u2019s Disease Research Group of the United K","year":"2008","unstructured":"Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson\u2019s Disease Research Group of the United K (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71(7):474\u2013480. doi: 10.1212\/01.wnl.0000310812.43352.66","journal-title":"Neurology"},{"key":"1722_CR255","doi-asserted-by":"publisher","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A (2003) Anticholinergics for symptomatic management of Parkinson\u2019s disease. Cochrane Database Syst Rev (2):CD003735. doi: 10.1002\/14651858.CD003735","DOI":"10.1002\/14651858.CD003735"},{"issue":"2\u20133","key":"1722_CR256","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-2999(92)90556-J","volume":"229","author":"JW Kebabian","year":"1992","unstructured":"Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (1992) A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229(2\u20133):203\u2013209","journal-title":"Eur J Pharmacol"},{"issue":"28","key":"1722_CR257","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1523\/JNEUROSCI.0942-10.2010","volume":"30","author":"AP Kells","year":"2010","unstructured":"Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, Narrow WC, Bowers WJ, Federoff HJ, Forsayeth J, Bankiewicz KS (2010) Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30(28):9567\u20139577. doi: 10.1523\/JNEUROSCI.0942-10.2010","journal-title":"J Neurosci"},{"issue":"4","key":"1722_CR258","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JPD-2011-11070","volume":"1","author":"T Kikuchi","year":"2011","unstructured":"Kikuchi T, Morizane A, Doi D, Onoe H, Hayashi T, Kawasaki T, Saiki H, Miyamoto S, Takahashi J (2011) Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson\u2019s disease. J Parkinsons Dis 1(4):395\u2013412. doi: 10.3233\/JPD-2011-11070","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"1722_CR259","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1073\/pnas.0536383100","volume":"100","author":"D Kirik","year":"2003","unstructured":"Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A 100(5):2884\u20132889. doi: 10.1073\/pnas.0536383100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1722_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2016.09.008","author":"D Kirik","year":"2016","unstructured":"Kirik D, Cederfjall E, Halliday G, Petersen A (2016) Gene therapy for Parkinson\u2019s disease: disease modification by GDNF family of ligands. Neurobiol Dis. doi: 10.1016\/j.nbd.2016.09.008","journal-title":"Neurobiol Dis"},{"key":"1722_CR261","first-page":"39","volume":"91","author":"SJ Kish","year":"2003","unstructured":"Kish SJ (2003) Biochemistry of Parkinson\u2019s disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson\u2019s disease? Adv Neurol 91:39\u201349","journal-title":"Adv Neurol"},{"issue":"Pt 1","key":"1722_CR262","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/brain\/awm239","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain 131(Pt 1):120\u2013131. doi: 10.1093\/brain\/awm239","journal-title":"Brain"},{"issue":"6676","key":"1722_CR263","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605\u2013608. doi: 10.1038\/33416","journal-title":"Nature"},{"key":"1722_CR264","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1692-0","author":"L Klingelhoefer","year":"2017","unstructured":"Klingelhoefer L, Reichmann H (2017) Parkinson\u2019s disease as a multisystem disorder. J Neural Transm (Vienna). doi: 10.1007\/s00702-017-1692-0","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"1722_CR265","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ana.410340413","volume":"34","author":"T Klockgether","year":"1993","unstructured":"Klockgether T, Turski L (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 34(4):585\u2013593. doi: 10.1002\/ana.410340413","journal-title":"Ann Neurol"},{"key":"1722_CR266","doi-asserted-by":"publisher","unstructured":"Ko WK, Camus SM, Li Q, Yang J, McGuire S, Pioli EY, Bezard E (2016) An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology 110 (Pt A):48-58. doi: 10.1016\/j.neuropharm.2016.07.012","DOI":"10.1016\/j.neuropharm.2016.07.012"},{"issue":"2","key":"1722_CR267","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","volume":"38","author":"Kondo T, Mizuno Y, Japanese Istradefylline Study G","year":"2015","unstructured":"Kondo T, Mizuno Y, Japanese Istradefylline Study G (2015) A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol 38(2):41\u201346. doi: 10.1097\/WNF.0000000000000073","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"1722_CR268","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/mds.23631","volume":"26","author":"JB Koprich","year":"2011","unstructured":"Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM (2011) The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson\u2019s disease. Mov Disord 26(7):1225\u20131233. doi: 10.1002\/mds.23631","journal-title":"Mov Disord"},{"key":"1722_CR269","doi-asserted-by":"crossref","unstructured":"Korczyn AD (2001) Dementia in Parkinson\u2019s disease. J Neurol 248 Suppl 3:III1-4","DOI":"10.1007\/PL00022916"},{"issue":"2","key":"1722_CR270","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.53.2.364","volume":"53","author":"AD Korczyn","year":"1999","unstructured":"Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson\u2019s disease. The 053 Study Group. Neurology 53(2):364\u2013370","journal-title":"Neurology"},{"issue":"1","key":"1722_CR271","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/npp.2008.161","volume":"34","author":"JH Kordower","year":"2009","unstructured":"Kordower JH, Brundin P (2009) Lewy body pathology in long-term fetal nigral transplants: is Parkinson\u2019s disease transmitted from one neural system to another? Neuropsychopharmacology 34(1):254. doi: 10.1038\/npp.2008.161","journal-title":"Neuropsychopharmacology"},{"issue":"5492","key":"1722_CR272","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"JH Kordower","year":"2000","unstructured":"Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease. Science 290(5492):767\u2013773","journal-title":"Science"},{"issue":"6","key":"1722_CR273","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, Bartus RT (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60(6):706\u2013715. doi: 10.1002\/ana.21032","journal-title":"Ann Neurol"},{"issue":"1","key":"1722_CR274","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00001756-200001170-00041","volume":"11","author":"NW Kowall","year":"2000","unstructured":"Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport 11(1):211\u2013213","journal-title":"NeuroReport"},{"issue":"7378","key":"1722_CR275","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature 480(7378):547\u2013551. doi: 10.1038\/nature10648","journal-title":"Nature"},{"issue":"9","key":"1722_CR276","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00702-007-0727-3","volume":"114","author":"M Kuoppamaki","year":"2007","unstructured":"Kuoppamaki M, Al-Barghouthy G, Jackson MJ, Smith LA, Quinn N, Jenner P (2007) L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J Neural Transm (Vienna) 114(9):1147\u20131153. doi: 10.1007\/s00702-007-0727-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"8\u20139","key":"1722_CR277","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s007020170018","volume":"108","author":"A Kupsch","year":"2001","unstructured":"Kupsch A, Sautter J, Gotz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna) 108(8\u20139):985\u20131009. doi: 10.1007\/s007020170018","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"1722_CR278","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JPD-160881","volume":"6","author":"Z Kurowska","year":"2016","unstructured":"Kurowska Z, Kordower JH, Stoessl AJ, Burke RE, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S (2016) Is Axonal Degeneration a Key Early Event in Parkinson\u2019s Disease? J Parkinsons Dis 6(4):703\u2013707. doi: 10.3233\/JPD-160881","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"1722_CR279","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1212\/01.wnl.0000257110.91041.5d","volume":"68","author":"AE Lang","year":"2007","unstructured":"Lang AE (2007) The progression of Parkinson disease: a hypothesis. Neurology 68(12):948\u2013952. doi: 10.1212\/01.wnl.0000257110.91041.5d","journal-title":"Neurology"},{"issue":"11","key":"1722_CR280","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.2220","volume":"16","author":"AE Lang","year":"2010","unstructured":"Lang AE (2010) Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 16(11):1223\u20131226. doi: 10.1038\/nm.2220","journal-title":"Nat Med"},{"issue":"15","key":"1722_CR281","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang AE, Lozano AM (1998) Parkinson\u2019s disease. First of two parts. N Engl J Med 339(15):1044\u20131053. doi: 10.1056\/NEJM199810083391506","journal-title":"N Engl J Med"},{"issue":"3","key":"1722_CR282","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459\u2013466. doi: 10.1002\/ana.20737","journal-title":"Ann Neurol"},{"issue":"1 Suppl","key":"1722_CR283","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1017\/S0317167100046333","volume":"11","author":"JW Langston","year":"1984","unstructured":"Langston JW, Ballard P (1984) Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson\u2019s disease. Can J Neurol Sci 11(1 Suppl):160\u2013165","journal-title":"Can J Neurol Sci"},{"issue":"4587","key":"1722_CR284","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979\u2013980","journal-title":"Science"},{"issue":"2","key":"1722_CR285","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","volume":"292","author":"JW Langston","year":"1984","unstructured":"Langston JW, Forno LS, Rebert CS, Irwin I (1984a) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292(2):390\u2013394","journal-title":"Brain Res"},{"key":"1722_CR286","first-page":"49","volume":"100","author":"JW Langston","year":"1984","unstructured":"Langston JW, Langston EB, Irwin I (1984b) MPTP-induced parkinsonism in human and non-human primates\u2013clinical and experimental aspects. Acta Neurol Scand Suppl 100:49\u201354","journal-title":"Acta Neurol Scand Suppl"},{"issue":"4 Suppl 1","key":"1722_CR287","first-page":"S79","volume":"47","author":"JW Langston","year":"2000","unstructured":"Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA (2000) Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 47(4 Suppl 1):S79\u201389","journal-title":"Ann Neurol"},{"issue":"5657","key":"1722_CR288","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/273059a0","volume":"273","author":"T Lee","year":"1978","unstructured":"Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson\u2019s disease. Nature 273(5657):59\u201361","journal-title":"Nature"},{"issue":"11","key":"1722_CR289","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/jnnp.44.11.1020","volume":"44","author":"AJ Lees","year":"1981","unstructured":"Lees AJ, Stern GM (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 44(11):1020\u20131023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1722_CR290","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archneur.1978.00500320023005","volume":"35","author":"AJ Lees","year":"1978","unstructured":"Lees AJ, Haddad S, Shaw KM, Kohout LJ, Stern GM (1978) Bromocriptine in parkinsonism. A long-term study. Arch Neurol 35(8):503\u2013505","journal-title":"A long-term study. Arch Neurol"},{"issue":"4","key":"1722_CR291","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A (2011) AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309\u2013319. doi: 10.1016\/S1474-4422(11)70039-4","journal-title":"Lancet Neurol"},{"issue":"5","key":"1722_CR292","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med 14(5):501\u2013503. doi: 10.1038\/nm1746","journal-title":"Nat Med"},{"issue":"8","key":"1722_CR293","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/mds.23012","volume":"25","author":"JY Li","year":"2010","unstructured":"Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, Brundin P (2010) Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson\u2019s disease. Mov Disord 25(8):1091\u20131096. doi: 10.1002\/mds.23012","journal-title":"Mov Disord"},{"issue":"1","key":"1722_CR294","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2011.09.013","volume":"87","author":"CA Lieu","year":"2012","unstructured":"Lieu CA, Subramanian T (2012) The interhemispheric connections of the striatum: implications for Parkinson\u2019s disease and drug-induced dyskinesias. Brain Res Bull 87(1):1\u20139. doi: 10.1016\/j.brainresbull.2011.09.013","journal-title":"Brain Res Bull"},{"issue":"8942","key":"1722_CR295","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(95)90062-4","volume":"345","author":"P Limousin","year":"1995","unstructured":"Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345(8942):91\u201395","journal-title":"Lancet"},{"issue":"7","key":"1722_CR296","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00018-015-2101-1","volume":"73","author":"D Lindholm","year":"2016","unstructured":"Lindholm D, Makela J, Di Liberto V, Mudo G, Belluardo N, Eriksson O, Saarma M (2016) Current disease modifying approaches to treat Parkinson\u2019s disease. Cell Mol Life Sci 73(7):1365\u20131379. doi: 10.1007\/s00018-015-2101-1","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1722_CR297","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00441-012-1362-3","volume":"349","author":"P Lingor","year":"2012","unstructured":"Lingor P, Koch JC, Tonges L, Bahr M (2012) Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res 349(1):289\u2013311. doi: 10.1007\/s00441-012-1362-3","journal-title":"Cell Tissue Res"},{"issue":"2","key":"1722_CR298","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jneumeth.2009.06.037","volume":"183","author":"N Liu","year":"2009","unstructured":"Liu N, Yue F, Tang WP, Chan P (2009) An objective measurement of locomotion behavior for hemiparkinsonian cynomolgus monkeys. J Neurosci Methods 183(2):188\u2013194. doi: 10.1016\/j.jneumeth.2009.06.037","journal-title":"J Neurosci Methods"},{"issue":"3","key":"1722_CR299","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.stem.2014.01.018","volume":"14","author":"H Liu","year":"2014","unstructured":"Liu H, Chen Y, Niu Y, Zhang K, Kang Y, Ge W, Liu X, Zhao E, Wang C, Lin S, Jing B, Si C, Lin Q, Chen X, Lin H, Pu X, Wang Y, Qin B, Wang F, Wang H, Si W, Zhou J, Tan T, Li T, Ji S, Xue Z, Luo Y, Cheng L, Zhou Q, Li S, Sun YE, Ji W (2014) TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. Cell Stem Cell 14(3):323\u2013328. doi: 10.1016\/j.stem.2014.01.018","journal-title":"Cell Stem Cell"},{"issue":"50","key":"1722_CR300","doi-asserted-by":"publisher","first-page":"17510","DOI":"10.1073\/pnas.0405313101","volume":"101","author":"C Lo Bianco","year":"2004","unstructured":"Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A 101(50):17510\u201317515. doi: 10.1073\/pnas.0405313101","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"1722_CR301","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1182\/blood-2009-02-204800","volume":"113","author":"YH Loh","year":"2009","unstructured":"Loh YH, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC, Kim K, Miller JD, Ng K, Daley GQ (2009) Generation of induced pluripotent stem cells from human blood. Blood 113(22):5476\u20135479. doi: 10.1182\/blood-2009-02-204800","journal-title":"Blood"},{"key":"1722_CR302","doi-asserted-by":"publisher","first-page":"5012129","DOI":"10.1155\/2017\/5012129","volume":"2017","author":"F Longhena","year":"2017","unstructured":"Longhena F, Faustini G, Missale C, Pizzi M, Spano P, Bellucci A (2017) The Contribution of alpha-Synuclein Spreading to Parkinson\u2019s Disease Synaptopathy. Neural Plast 2017:5012129. doi: 10.1155\/2017\/5012129","journal-title":"Neural Plast"},{"issue":"3","key":"1722_CR303","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0014-2999(89)90348-8","volume":"166","author":"PA Loschmann","year":"1989","unstructured":"Loschmann PA, Chong PN, Nomoto M, Tepper PG, Horn AS, Jenner P, Marsden CD (1989) Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur J Pharmacol 166(3):373\u2013380","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"1722_CR304","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02245479","volume":"109","author":"PA Loschmann","year":"1992","unstructured":"Loschmann PA, Smith LA, Lange KW, Jahnig P, Jenner P, Marsden CD (1992) Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109(1\u20132):49\u201356","journal-title":"Psychopharmacology"},{"issue":"7","key":"1722_CR305","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/14656566.2016.1149163","volume":"17","author":"M Lotia","year":"2016","unstructured":"Lotia M, Jankovic J (2016) New and emerging medical therapies in Parkinson\u2019s disease. Expert Opin Pharmacother 17(7):895\u2013909. doi: 10.1517\/14656566.2016.1149163","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"1722_CR306","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm0705-703","volume":"11","author":"S Love","year":"2005","unstructured":"Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11(7):703\u2013704. doi: 10.1038\/nm0705-703","journal-title":"Nat Med"},{"issue":"2","key":"1722_CR307","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nbd.2011.12.038","volume":"48","author":"K Low","year":"2012","unstructured":"Low K, Aebischer P (2012) Use of viral vectors to create animal models for Parkinson\u2019s disease. Neurobiol Dis 48(2):189\u2013201. doi: 10.1016\/j.nbd.2011.12.038","journal-title":"Neurobiol Dis"},{"issue":"5","key":"1722_CR308","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ana.410310514","volume":"31","author":"MR Luquin","year":"1992","unstructured":"Luquin MR, Laguna J, Obeso JA (1992) Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 31(5):551\u2013554. doi: 10.1002\/ana.410310514","journal-title":"Ann Neurol"},{"issue":"52","key":"1722_CR309","doi-asserted-by":"publisher","first-page":"14245","DOI":"10.1523\/JNEUROSCI.4199-08.2008","volume":"28","author":"N Mallet","year":"2008","unstructured":"Mallet N, Pogosyan A, Marton LF, Bolam JP, Brown P, Magill PJ (2008) Parkinsonian beta oscillations in the external globus pallidus and their relationship with subthalamic nucleus activity. J Neurosci 28(52):14245\u201314258. doi: 10.1523\/JNEUROSCI.4199-08.2008","journal-title":"J Neurosci"},{"key":"1722_CR310","unstructured":"Maloney R, Shanks S, Maloney J (2010) The application of low-level laser therapy for the symptomatic care of late stage Parkinson\u2019sdisease:a non-controlled, non-randomized study [Abstract]. Am Soc Laser Med Surg:185"},{"issue":"6","key":"1722_CR311","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/mds.10281","volume":"17","author":"AJ Manson","year":"2002","unstructured":"Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson\u2019s disease: long-term follow-up study of 64 patients. Mov Disord 17(6):1235\u20131241. doi: 10.1002\/mds.10281","journal-title":"Mov Disord"},{"issue":"4","key":"1722_CR312","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","volume":"16","author":"EC Maratos","year":"2001","unstructured":"Maratos EC, Jackson MJ, Pearce RK, Jenner P (2001) Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16(4):631\u2013641","journal-title":"Mov Disord"},{"issue":"5","key":"1722_CR313","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol 7(5):400\u2013408. doi: 10.1016\/S1474-4422(08)70065-6","journal-title":"Lancet Neurol"},{"issue":"12","key":"1722_CR314","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW (2010) Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164\u20131172. doi: 10.1016\/S1474-4422(10)70254-4","journal-title":"Lancet Neurol"},{"issue":"8","key":"1722_CR315","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mds.26510","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras C, Chaudhuri KR (2016) Nonmotor features of Parkinson\u2019s disease subtypes. Mov Disord 31(8):1095\u20131102. doi: 10.1002\/mds.26510","journal-title":"Mov Disord"},{"issue":"8","key":"1722_CR316","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"R Martinez-Fernandez","year":"2016","unstructured":"Martinez-Fernandez R, Schmitt E, Martinez-Martin P, Krack P (2016) The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations. Mov Disord 31(8):1080\u20131094. doi: 10.1002\/mds.26731","journal-title":"Mov Disord"},{"issue":"Pt 7","key":"1722_CR317","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/brain\/awr137","volume":"134","author":"GJ Masilamoni","year":"2011","unstructured":"Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y (2011) Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 134(Pt 7):2057\u20132073. doi: 10.1093\/brain\/awr137","journal-title":"Brain"},{"issue":"5","key":"1722_CR318","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0197-4580(02)00022-2","volume":"23","author":"N Maswood","year":"2002","unstructured":"Maswood N, Grondin R, Zhang Z, Stanford JA, Surgener SP, Gash DM, Gerhardt GA (2002) Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23(5):881\u2013889","journal-title":"Neurobiol Aging"},{"issue":"12","key":"1722_CR319","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJM198509193131204","volume":"313","author":"R Mayeux","year":"1985","unstructured":"Mayeux R, Stern Y, Mulvey K, Cote L (1985) Reappraisal of temporary levodopa withdrawal (\u201cdrug holiday\u201d) in Parkinson\u2019s disease. N Engl J Med 313(12):724\u2013728. doi: 10.1056\/NEJM198509193131204","journal-title":"N Engl J Med"},{"issue":"8","key":"1722_CR320","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/NEN.0b013e318180f0bd","volume":"67","author":"AL McCormack","year":"2008","unstructured":"McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, Di Monte DA (2008) Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol 67(8):793\u2013802. doi: 10.1097\/NEN.0b013e318180f0bd","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"1722_CR321","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","volume":"26","author":"NB Mercuri","year":"2005","unstructured":"Mercuri NB, Bernardi G (2005) The \u2018magic\u2019 of L-dopa: why is it the gold standard Parkinson\u2019s disease therapy? Trends Pharmacol Sci 26(7):341\u2013344. doi: 10.1016\/j.tips.2005.05.002","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1722_CR322","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/2013.jamaneurol.45","volume":"70","author":"S Miocinovic","year":"2013","unstructured":"Miocinovic S, Somayajula S, Chitnis S, Vitek JL (2013) History, applications, and mechanisms of deep brain stimulation. JAMA Neurol 70(2):163\u2013171. doi: 10.1001\/2013.jamaneurol.45","journal-title":"JAMA Neurol"},{"issue":"1\u20132","key":"1722_CR323","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(85)90424-0","volume":"61","author":"IJ Mitchell","year":"1985","unstructured":"Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR (1985) Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett 61(1\u20132):195\u2013200","journal-title":"Neurosci Lett"},{"issue":"3","key":"1722_CR324","first-page":"491","volume":"68","author":"SJ Mitchell","year":"1987","unstructured":"Mitchell SJ, Richardson RT, Baker FH, DeLong MR (1987) The primate globus pallidus: neuronal activity related to direction of movement. Exp Brain Res 68(3):491\u2013505","journal-title":"Exp Brain Res"},{"issue":"5\u20136","key":"1722_CR325","first-page":"492","volume":"6","author":"IJ Mitchell","year":"1995","unstructured":"Mitchell IJ, Hughes N, Carroll CB, Brotchie JM (1995) Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav Pharmacol 6(5\u20136):492\u2013507","journal-title":"Behav Pharmacol"},{"issue":"4","key":"1722_CR326","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS (2012) Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum Gene Ther 23(4):377\u2013381. doi: 10.1089\/hum.2011.220","journal-title":"Hum Gene Ther"},{"issue":"2","key":"1722_CR327","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ana.410420212","volume":"42","author":"Y Miyoshi","year":"1997","unstructured":"Miyoshi Y, Zhang Z, Ovadia A, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM (1997) Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 42(2):208\u2013214. doi: 10.1002\/ana.410420212","journal-title":"Ann Neurol"},{"key":"1722_CR328","first-page":"665","volume-title":"Advanced Neurology","author":"RJ Mones","year":"1973","unstructured":"Mones RJ (1973) Experimental Dyskinesias in Normal Rhesus Monkeys. In: Barbeau A, Chase TN, Paulson GW (eds) Advanced Neurology, vol 1. Raven Press, New York, pp 665\u2013669"},{"key":"1722_CR329","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-12-801022-8.00007-6","volume":"119","author":"N Morin","year":"2014","unstructured":"Morin N, Di Paolo T (2014) Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson\u2019s disease. Int Rev Neurobiol 119:151\u2013167. doi: 10.1016\/B978-0-12-801022-8.00007-6","journal-title":"Int Rev Neurobiol"},{"issue":"7","key":"1722_CR330","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","volume":"58","author":"N Morin","year":"2010","unstructured":"Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58(7):981\u2013986. doi: 10.1016\/j.neuropharm.2009.12.024","journal-title":"Neuropharmacology"},{"key":"1722_CR331","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","volume":"66","author":"N Morin","year":"2013","unstructured":"Morin N, Gregoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T (2013a) MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 66:355\u2013364. doi: 10.1016\/j.neuropharm.2012.07.036","journal-title":"Neuropharmacology"},{"key":"1722_CR332","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","volume":"73","author":"N Morin","year":"2013","unstructured":"Morin N, Morissette M, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2013b) Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 73:216\u2013231. doi: 10.1016\/j.neuropharm.2013.05.028","journal-title":"Neuropharmacology"},{"key":"1722_CR333","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.expneurol.2013.01.024","volume":"256","author":"N Morin","year":"2014","unstructured":"Morin N, Jourdain VA, Di Paolo T (2014) Modeling dyskinesia in animal models of Parkinson disease. Exp Neurol 256:105\u2013116. doi: 10.1016\/j.expneurol.2013.01.024","journal-title":"Exp Neurol"},{"key":"1722_CR334","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pnpbp.2014.07.006","volume":"56","author":"N Morin","year":"2015","unstructured":"Morin N, Morissette M, Gregoire L, Di Paolo T (2015a) Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry 56:27\u201338. doi: 10.1016\/j.pnpbp.2014.07.006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1722_CR335","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.neuropharm.2015.08.002","volume":"99","author":"N Morin","year":"2015","unstructured":"Morin N, Morissette M, Gregoire L, Rajput A, Rajput AH, Di Paolo T (2015b) Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications. Neuropharmacology 99:356\u2013368. doi: 10.1016\/j.neuropharm.2015.08.002","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"1722_CR336","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","volume":"49","author":"M Morissette","year":"1997","unstructured":"Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bedard PJ, Di Paolo T (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49(1\u20132):55\u201362","journal-title":"Brain Res Mol Brain Res"},{"issue":"8","key":"1722_CR337","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1046\/j.1460-9568.1998.00264.x","volume":"10","author":"M Morissette","year":"1998","unstructured":"Morissette M, Goulet M, Grondin R, Blanchet P, Bedard PJ, Di Paolo T, Levesque D (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10(8):2565\u20132573","journal-title":"Eur J Neurosci"},{"issue":"3","key":"1722_CR338","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/syn.20295","volume":"60","author":"M Morissette","year":"2006","unstructured":"Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bedard PJ, Di Paolo T (2006a) Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse 60(3):239\u2013250. doi: 10.1002\/syn.20295","journal-title":"Synapse"},{"issue":"1","key":"1722_CR339","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/mds.20654","volume":"21","author":"M Morissette","year":"2006","unstructured":"Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bedard PJ, Di Paolo T (2006b) Prevention of levodopa-induced dyskinesias by a selective NR1A\/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 21(1):9\u201317. doi: 10.1002\/mds.20654","journal-title":"Mov Disord"},{"key":"1722_CR340","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bcp.2016.03.023","volume":"109","author":"M Morissette","year":"2016","unstructured":"Morissette M, Morin N, Gregoire L, Rajput A, Rajput AH, Di Paolo T (2016) Brain alpha7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients. Biochem Pharmacol 109:62\u201369. doi: 10.1016\/j.bcp.2016.03.023","journal-title":"Biochem Pharmacol"},{"key":"1722_CR341","doi-asserted-by":"publisher","unstructured":"Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S, Takahashi J (2013) Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports 1 (4):283-292. doi: 10.1016\/j.stemcr.2013.08.007","DOI":"10.1016\/j.stemcr.2013.08.007"},{"key":"1722_CR342","doi-asserted-by":"publisher","unstructured":"Moro C, El Massri N, Darlot F, Torres N, Chabrol C, Agay D, Auboiroux V, Johnstone DM, Stone J, Mitrofanis J, Benabid AL (2016) Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson\u2019s disease. Brain Res 1648 (Pt A):19-26. doi: 10.1016\/j.brainres.2016.07.005","DOI":"10.1016\/j.brainres.2016.07.005"},{"issue":"3","key":"1722_CR343","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/10430340252792486","volume":"13","author":"S Muramatsu","year":"2002","unstructured":"Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I, Ozawa K (2002) Behavioral recovery in a primate model of Parkinson\u2019s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13(3):345\u2013354. doi: 10.1089\/10430340252792486","journal-title":"Hum Gene Ther"},{"issue":"9","key":"1722_CR344","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"S Muramatsu","year":"2010","unstructured":"Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, Nakano I (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol Ther 18(9):1731\u20131735. doi: 10.1038\/mt.2010.135","journal-title":"Mol Ther"},{"issue":"4","key":"1722_CR345","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1152\/jn.1995.74.4.1800","volume":"74","author":"A Nini","year":"1995","unstructured":"Nini A, Feingold A, Slovin H, Bergman H (1995) Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. J Neurophysiol 74(4):1800\u20131805","journal-title":"J Neurophysiol"},{"issue":"41","key":"1722_CR346","doi-asserted-by":"publisher","first-page":"17663","DOI":"10.1073\/pnas.1006563107","volume":"107","author":"Y Niu","year":"2010","unstructured":"Niu Y, Yu Y, Bernat A, Yang S, He X, Guo X, Chen D, Chen Y, Ji S, Si W, Lv Y, Tan T, Wei Q, Wang H, Shi L, Guan J, Zhu X, Afanassieff M, Savatier P, Zhang K, Zhou Q, Ji W (2010) Transgenic rhesus monkeys produced by gene transfer into early-cleavage-stage embryos using a simian immunodeficiency virus-based vector. Proc Natl Acad Sci U S A 107(41):17663\u201317667. doi: 10.1073\/pnas.1006563107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1722_CR347","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.cell.2014.01.027","volume":"156","author":"Y Niu","year":"2014","unstructured":"Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J (2014) Generation of gene-modified cynomolgus monkey via Cas9\/RNA-mediated gene targeting in one-cell embryos. Cell 156(4):836\u2013843. doi: 10.1016\/j.cell.2014.01.027","journal-title":"Cell"},{"issue":"8","key":"1722_CR348","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/hmg\/ddu748","volume":"24","author":"Y Niu","year":"2015","unstructured":"Niu Y, Guo X, Chen Y, Wang CE, Gao J, Yang W, Kang Y, Si W, Wang H, Yang SH, Li S, Ji W, Li XJ (2015) Early Parkinson\u2019s disease symptoms in alpha-synuclein transgenic monkeys. Hum Mol Genet 24(8):2308\u20132317. doi: 10.1093\/hmg\/ddu748","journal-title":"Hum Mol Genet"},{"issue":"2\u20133","key":"1722_CR349","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0304-3940(88)90095-X","volume":"93","author":"M Nomoto","year":"1988","unstructured":"Nomoto M, Jenner P, Marsden CD (1988) The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset. Neurosci Lett 93(2\u20133):275\u2013280","journal-title":"Neurosci Lett"},{"issue":"6","key":"1722_CR350","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ana.23687","volume":"72","author":"AJ Noyce","year":"2012","unstructured":"Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A (2012) Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72(6):893\u2013901. doi: 10.1002\/ana.23687","journal-title":"Ann Neurol"},{"issue":"10 Suppl","key":"1722_CR351","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S1471-1931(00)00029-X","volume":"23","author":"JG Nutt","year":"2000","unstructured":"Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine-receptor stimulation in advanced Parkinson\u2019s disease. Trends Neurosci 23(10 Suppl):S109\u2013115","journal-title":"Trends Neurosci"},{"issue":"1","key":"1722_CR352","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","volume":"60","author":"JG Nutt","year":"2003","unstructured":"Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF, Factor IGSGIiGcl-dn (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1):69\u201373","journal-title":"Neurology"},{"issue":"12 Suppl 6","key":"1722_CR353","first-page":"S7","volume":"55","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Macias R, Alvarez L, Guridi J, Vitek J, DeLong MR (2000) Pathophysiologic basis of surgery for Parkinson\u2019s disease. Neurology 55(12 Suppl 6):S7\u201312","journal-title":"Neurology"},{"issue":"1","key":"1722_CR354","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/mds.1272","volume":"17","author":"MC Obinu","year":"2002","unstructured":"Obinu MC, Reibaud M, Blanchard V, Moussaoui S, Imperato A (2002) Neuroprotective effect of riluzole in a primate model of Parkinson\u2019s disease: behavioral and histological evidence. Mov Disord 17(1):13\u201319","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"1722_CR355","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jnc.13750","volume":"139","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem 139(Suppl 1):325\u2013337. doi: 10.1111\/jnc.13750","journal-title":"J Neurochem"},{"key":"1722_CR356","doi-asserted-by":"crossref","unstructured":"Oiwa Y, Nakai K, Itakura T (2006) Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys. Neurol Med Chir (Tokyo) 46 (6):267-275; discussion 275-266","DOI":"10.2176\/nmc.46.267"},{"issue":"5","key":"1722_CR357","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ana.21596","volume":"65","author":"MS Okun","year":"2009","unstructured":"Okun MS, Fernandez HH, Wu SS, Kirsch-Darrow L, Bowers D, Bova F, Suelter M, Jacobson CEt, Wang X, Gordon CW, Zeilman P, Romrell J, Martin P, Ward H, Rodriguez RL, Foote KD (2009) Cognition and mood in Parkinson\u2019s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 65(5):586\u2013595. doi: 10.1002\/ana.21596","journal-title":"Ann Neurol"},{"key":"1722_CR358","unstructured":"Olanow CW, Obeso JA (2000) Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson\u2019s disease: implications for the early use of COMT inhibitors. Neurology 55 (11 Suppl 4):S72-77; discussion S78-81"},{"issue":"8","key":"1722_CR359","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5(8):677\u2013687. doi: 10.1016\/S1474-4422(06)70521-X","journal-title":"Lancet Neurol"},{"issue":"2","key":"1722_CR360","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"C Olanow","year":"2015","unstructured":"Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78(2):248\u2013257. doi: 10.1002\/ana.24436","journal-title":"Ann Neurol"},{"issue":"2","key":"1722_CR361","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s12031-008-9137-8","volume":"38","author":"B Ouattara","year":"2009","unstructured":"Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Gregoire L, Meltzer LT, Di Paolo T (2009) Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci 38(2):128\u2013142. doi: 10.1007\/s12031-008-9137-8","journal-title":"J Mol Neurosci"},{"issue":"3","key":"1722_CR362","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1471-4159.2010.06635.x","volume":"113","author":"B Ouattara","year":"2010","unstructured":"Ouattara B, Gasparini F, Morissette M, Gregoire L, Samadi P, Gomez-Mancilla B, Di Paolo T (2010a) Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113(3):715\u2013724. doi: 10.1111\/j.1471-4159.2010.06635.x","journal-title":"J Neurochem"},{"issue":"4","key":"1722_CR363","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","volume":"167","author":"B Ouattara","year":"2010","unstructured":"Ouattara B, Hoyer D, Gregoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T (2010b) Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 167(4):1160\u20131167. doi: 10.1016\/j.neuroscience.2010.03.022","journal-title":"Neuroscience"},{"issue":"1","key":"1722_CR364","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0306-4522(93)90462-O","volume":"55","author":"RD Page","year":"1993","unstructured":"Page RD, Sambrook MA, Crossman AR (1993) Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. Neuroscience 55(1):147\u2013165","journal-title":"Neuroscience"},{"issue":"4","key":"1722_CR365","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1185\/03007990902779319","volume":"25","author":"R Pahwa","year":"2009","unstructured":"Pahwa R, Lyons KE (2009) Levodopa-related wearing-off in Parkinson\u2019s disease: identification and management. Curr Med Res Opin 25(4):841\u2013849. doi: 10.1185\/03007990902779319","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1722_CR366","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.26159","volume":"30","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ (2015) Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study). Mov Disord 30(6):788\u2013795. doi: 10.1002\/mds.26159","journal-title":"Mov Disord"},{"issue":"9923","key":"1722_CR367","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugieres P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383(9923):1138\u20131146. doi: 10.1016\/S0140-6736(13)61939-X","journal-title":"Lancet"},{"issue":"5","key":"1722_CR368","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ana.410420511","volume":"42","author":"Parkinson Study Group","year":"1997","unstructured":"Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients. Parkinson Study Group. Ann Neurol 42(5):747\u2013755. doi: 10.1002\/ana.410420511","journal-title":"Parkinson Study Group. Ann Neurol"},{"issue":"15","key":"1722_CR369","first-page":"1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931\u20131938","journal-title":"Parkinson Study Group. JAMA"},{"issue":"2","key":"1722_CR370","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.20374","volume":"57","author":"NK Patel","year":"2005","unstructured":"Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57(2):298\u2013302. doi: 10.1002\/ana.20374","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"1722_CR371","first-page":"9","volume":"14","author":"RK Pearce","year":"1999","unstructured":"Pearce RK (1999) L-dopa and dyskinesias in normal monkeys. Mov Disord 14(Suppl 1):9\u201312","journal-title":"Mov Disord"},{"issue":"6","key":"1722_CR372","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/mds.870100606","volume":"10","author":"RK Pearce","year":"1995","unstructured":"Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 10(6):731\u2013740. doi: 10.1002\/mds.870100606","journal-title":"Mov Disord"},{"issue":"2","key":"1722_CR373","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/mds.870130207","volume":"13","author":"RK Pearce","year":"1998","unstructured":"Pearce RK, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13(2):234\u2013241. doi: 10.1002\/mds.870130207","journal-title":"Mov Disord"},{"issue":"4","key":"1722_CR374","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130100733","volume":"156","author":"RK Pearce","year":"2001","unstructured":"Pearce RK, Heikkila M, Linden IB, Jenner P (2001) L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology 156(4):402\u2013409","journal-title":"Psychopharmacology"},{"issue":"5","key":"1722_CR375","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/mds.10238","volume":"17","author":"RK Pearce","year":"2002","unstructured":"Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, Jenner P (2002) The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord 17(5):877\u2013886. doi: 10.1002\/mds.10238","journal-title":"Mov Disord"},{"issue":"18","key":"1722_CR376","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1080\/14656566.2016.1254189","volume":"17","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Peralta MC, Barrantes FJ (2016) Pharmacotherapies for Parkinson\u2019s disease symptoms related to cholinergic degeneration. Expert Opin Pharmacother 17(18):2405\u20132415. doi: 10.1080\/14656566.2016.1254189","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1722_CR377","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.0953-816X.2003.03088.x","volume":"19","author":"M Pessiglione","year":"2004","unstructured":"Pessiglione M, Guehl D, Hirsch EC, Feger J, Tremblay L (2004) Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity. Eur J Neurosci 19(2):426\u2013436","journal-title":"Eur J Neurosci"},{"issue":"3","key":"1722_CR378","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0306-4522(91)90080-8","volume":"44","author":"C Pifl","year":"1991","unstructured":"Pifl C, Schingnitz G, Hornykiewicz O (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44(3):591\u2013605","journal-title":"Neuroscience"},{"issue":"5","key":"1722_CR379","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","volume":"28","author":"A Pinna","year":"2014","unstructured":"Pinna A (2014) Adenosine A2A receptor antagonists in Parkinson\u2019s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28(5):455\u2013474. doi: 10.1007\/s40263-014-0161-7","journal-title":"CNS Drugs"},{"key":"1722_CR380","doi-asserted-by":"publisher","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Bjorklund A, Lindvall O, Piccini P (2012) Serotonin neuron loss and nonmotor symptoms continue in Parkinson\u2019s patients treated with dopamine grafts. Sci Transl Med 4 (128):128ra141. doi: 10.1126\/scitranslmed.3003391","DOI":"10.1126\/scitranslmed.3003391"},{"issue":"2","key":"1722_CR381","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.26077","volume":"30","author":"C Pont-Sunyer","year":"2015","unstructured":"Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brucke T, Bayes A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Alvarez R, Ispierto L, De Fabregues O, Callen A, Palasi A, Aguilar M, Marti MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E (2015) The onset of nonmotor symptoms in Parkinson\u2019s disease (the ONSET PD study). Mov Disord 30(2):229\u2013237. doi: 10.1002\/mds.26077","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR382","doi-asserted-by":"publisher","first-page":"a009308","DOI":"10.1101\/cshperspect.a009308","volume":"2","author":"G Porras","year":"2012","unstructured":"Porras G, Li Q, Bezard E (2012) Modeling Parkinson\u2019s disease in primates: the MPTP model. Cold Spring Harb Perspect Med 2(3):a009308. doi: 10.1101\/cshperspect.a009308","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"1722_CR383","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","volume":"12","author":"RB Postuma","year":"2016","unstructured":"Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622\u2013634. doi: 10.1038\/nrneurol.2016.152","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"1722_CR384","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. doi: 10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"1722_CR385","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2013.09.014","volume":"256","author":"LF Potts","year":"2014","unstructured":"Potts LF, Wu H, Singh A, Marcilla I, Luquin MR, Papa SM (2014) Modeling Parkinson\u2019s disease in monkeys for translational studies, a critical analysis. Exp Neurol 256:133\u2013143. doi: 10.1016\/j.expneurol.2013.09.014","journal-title":"Exp Neurol"},{"issue":"13","key":"1722_CR386","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583\u20131590. doi: 10.1002\/mds.25945","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR387","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","volume":"67","author":"S Przedborski","year":"1995","unstructured":"Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67(3):631\u2013647","journal-title":"Neuroscience"},{"issue":"3","key":"1722_CR388","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.nbd.2005.05.028","volume":"20","author":"MG Purisai","year":"2005","unstructured":"Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA (2005) Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20(3):898\u2013906. doi: 10.1016\/j.nbd.2005.05.028","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1722_CR389","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.parkreldis.2013.01.020","volume":"19","author":"A Puschmann","year":"2013","unstructured":"Puschmann A (2013) Monogenic Parkinson\u2019s disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 19(4):407\u2013415. doi: 10.1016\/j.parkreldis.2013.01.020","journal-title":"Parkinsonism Relat Disord"},{"key":"1722_CR390","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.09.090","author":"C Quek","year":"2016","unstructured":"Quek C, Hill AF (2016) The role of extracellular vesicles in neurodegenerative diseases. Biochem Biophys Res Commun. doi: 10.1016\/j.bbrc.2016.09.090","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1722_CR391","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0306-4522(00)00130-5","volume":"98","author":"M Quik","year":"2000","unstructured":"Quik M, Police S, He L, Di Monte DA, Langston JW (2000) Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 98(2):263\u2013273","journal-title":"Neuroscience"},{"issue":"3","key":"1722_CR392","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1212\/WNL.0b013e3181ae7af1","volume":"73","author":"AH Rajput","year":"2009","unstructured":"Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73(3):206\u2013212. doi: 10.1212\/WNL.0b013e3181ae7af1","journal-title":"Neurology"},{"issue":"5","key":"1722_CR393","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archneur.65.5.577","volume":"65","author":"Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T, Group AS","year":"2008","unstructured":"Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T, Group AS (2008) Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 65(5):577\u2013583. doi: 10.1001\/archneur.65.5.577","journal-title":"Arch Neurol"},{"issue":"2","key":"1722_CR394","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/jnnp.42.2.143","volume":"42","author":"A Rascol","year":"1979","unstructured":"Rascol A, Guiraud B, Montastruc JL, David J, Clanet M (1979) Long-term treatment of Parkinson\u2019s disease with bromocriptine. J Neurol Neurosurg Psychiatry 42(2):143\u2013150","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1722_CR395","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13","author":"O Rascol","year":"1998","unstructured":"Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F (1998) Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 13(1):39\u201345. doi: 10.1002\/mds.870130111","journal-title":"Mov Disord"},{"issue":"20","key":"1722_CR396","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342(20):1484\u20131491. doi: 10.1056\/NEJM200005183422004","journal-title":"N Engl J Med"},{"issue":"9463","key":"1722_CR397","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, Group Ls (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947\u2013954. doi: 10.1016\/S0140-6736(05)71083-7","journal-title":"Lancet"},{"issue":"9","key":"1722_CR398","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","volume":"20","author":"O Rascol","year":"2014","unstructured":"Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B (2014) Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 20(9):947\u2013956. doi: 10.1016\/j.parkreldis.2014.05.003","journal-title":"Parkinsonism Relat Disord"},{"issue":"22","key":"1722_CR399","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1523\/JNEUROSCI.20-22-08559.2000","volume":"20","author":"A Raz","year":"2000","unstructured":"Raz A, Vaadia E, Bergman H (2000) Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. J Neurosci 20(22):8559\u20138571","journal-title":"J Neurosci"},{"issue":"29","key":"1722_CR400","doi-asserted-by":"publisher","first-page":"12175","DOI":"10.1073\/pnas.0704091104","volume":"104","author":"DE Redmond Jr","year":"2007","unstructured":"Redmond DE Jr, Bjugstad KB, Teng YD, Ourednik V, Ourednik J, Wakeman DR, Parsons XH, Gonzalez R, Blanchard BC, Kim SU, Gu Z, Lipton SA, Markakis EA, Roth RH, Elsworth JD, Sladek JR Jr, Sidman RL, Snyder EY (2007) Behavioral improvement in a primate Parkinson\u2019s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A 104(29):12175\u201312180. doi: 10.1073\/pnas.0704091104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1722_CR401","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nbd.2007.08.008","volume":"29","author":"DE Redmond Jr","year":"2008","unstructured":"Redmond DE Jr, Vinuela A, Kordower JH, Isacson O (2008) Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson\u2019s disease. Neurobiol Dis 29(1):103\u2013116. doi: 10.1016\/j.nbd.2007.08.008","journal-title":"Neurobiol Dis"},{"issue":"5","key":"1722_CR402","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.parkreldis.2008.09.003","volume":"15","author":"JS Reijnders","year":"2009","unstructured":"Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF (2009) The association between motor subtypes and psychopathology in Parkinson\u2019s disease. Parkinsonism Relat Disord 15(5):379\u2013382. doi: 10.1016\/j.parkreldis.2008.09.003","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"1722_CR403","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","volume":"33","author":"G Riahi","year":"2011","unstructured":"Riahi G, Morissette M, Parent M, Di Paolo T (2011) Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 33(10):1823\u20131831. doi: 10.1111\/j.1460-9568.2011.07675.x","journal-title":"Eur J Neurosci"},{"issue":"7","key":"1722_CR404","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.neuint.2012.08.009","volume":"61","author":"G Riahi","year":"2012","unstructured":"Riahi G, Morissette M, Levesque D, Rouillard C, Samadi P, Parent M, Di Paolo T (2012) Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain. Neurochem Int 61(7):1160\u20131171. doi: 10.1016\/j.neuint.2012.08.009","journal-title":"Neurochem Int"},{"issue":"1","key":"1722_CR405","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","volume":"20","author":"P Riederer","year":"2011","unstructured":"Riederer P, Laux G (2011) MAO-inhibitors in Parkinson\u2019s Disease. Exp Neurobiol 20(1):1\u201317. doi: 10.5607\/en.2011.20.1.1","journal-title":"MAO-inhibitors in Parkinson\u2019s Disease. Exp Neurobiol"},{"issue":"3\u20134","key":"1722_CR406","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01249445","volume":"38","author":"P Riederer","year":"1976","unstructured":"Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in parkinson\u2019s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38(3\u20134):277\u2013301","journal-title":"J Neural Transm"},{"issue":"2","key":"1722_CR407","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1212\/WNL.48.2.363","volume":"48","author":"UK Rinne","year":"1997","unstructured":"Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R (1997) Cabergoline in the treatment of early Parkinson\u2019s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48(2):363\u2013368","journal-title":"Neurology"},{"key":"1722_CR408","doi-asserted-by":"crossref","unstructured":"Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998a) Early treatment of Parkinson\u2019s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 Suppl 1:23-30","DOI":"10.2165\/00003495-199855001-00004"},{"issue":"5","key":"1722_CR409","first-page":"1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998b) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309\u20131314","journal-title":"Nomecomt Study Group. Neurology"},{"issue":"3 Suppl 1","key":"1722_CR410","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1002\/ana.410440726","volume":"44","author":"MC Rodriguez","year":"1998","unstructured":"Rodriguez MC, Obeso JA, Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson\u2019s disease: a target for neuroprotection. Ann Neurol 44(3 Suppl 1):S175\u2013188","journal-title":"Ann Neurol"},{"issue":"2","key":"1722_CR411","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0166-4328(94)90138-4","volume":"60","author":"DP Roeltgen","year":"1994","unstructured":"Roeltgen DP, Schneider JS (1994) Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys. Behav Brain Res 60(2):115\u2013124","journal-title":"Behav Brain Res"},{"key":"1722_CR412","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nbd.2013.09.006","volume":"62","author":"R Rosenbaum","year":"2014","unstructured":"Rosenbaum R, Zimnik A, Zheng F, Turner RS, Alzheimer C, Doiron B, Rubin JE (2014) Axonal and synaptic failure suppress the transfer of firing rate oscillations, synchrony and information during high frequency deep brain stimulation. Neurobiol Dis 62:86\u201399. doi: 10.1016\/j.nbd.2013.09.006","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1722_CR413","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199619040-00001","volume":"19","author":"HM Ruottinen","year":"1996","unstructured":"Ruottinen HM, Rinne UK (1996) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson\u2019s disease. Clin Neuropharmacol 19(4):283\u2013296","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"1722_CR414","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","volume":"39","author":"D Rylander","year":"2010","unstructured":"Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA (2010a) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39(3):352\u2013361. doi: 10.1016\/j.nbd.2010.05.001","journal-title":"Neurobiol Dis"},{"issue":"5","key":"1722_CR415","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ana.22097","volume":"68","author":"D Rylander","year":"2010","unstructured":"Rylander D, Parent M, O\u2019Sullivan SS, Dovero S, Lees AJ, Bezard E, Descarries L, Cenci MA (2010b) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68(5):619\u2013628. doi: 10.1002\/ana.22097","journal-title":"Ann Neurol"},{"issue":"5","key":"1722_CR416","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.870130506","volume":"13","author":"HL Ryoo","year":"1998","unstructured":"Ryoo HL, Pierrotti D, Joyce JN (1998) Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson\u2019s disease. Mov Disord 13(5):788\u2013797. doi: 10.1002\/mds.870130506","journal-title":"Mov Disord"},{"issue":"1","key":"1722_CR417","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1471-4159.2004.02496.x","volume":"90","author":"MF Salvatore","year":"2004","unstructured":"Salvatore MF, Zhang JL, Large DM, Wilson PE, Gash CR, Thomas TC, Haycock JW, Bing G, Stanford JA, Gash DM, Gerhardt GA (2004) Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem 90(1):245\u2013254. doi: 10.1111\/j.1471-4159.2004.02496.x","journal-title":"J Neurochem"},{"issue":"2","key":"1722_CR418","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ana.20738","volume":"59","author":"P Samadi","year":"2006","unstructured":"Samadi P, Gregoire L, Rouillard C, Bedard PJ, Di Paolo T, Levesque D (2006) Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 59(2):282\u2013288. doi: 10.1002\/ana.20738","journal-title":"Ann Neurol"},{"issue":"7","key":"1722_CR419","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","volume":"29","author":"P Samadi","year":"2008","unstructured":"Samadi P, Gregoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bedard PJ, Di Paolo T (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 29(7):1040\u20131051. doi: 10.1016\/j.neurobiolaging.2007.02.005","journal-title":"Neurobiol Aging"},{"key":"1722_CR420","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-12-381328-2.00006-7","volume":"98","author":"T Sankar","year":"2011","unstructured":"Sankar T, Lozano AM (2011) Surgical approach to l-dopa-induced dyskinesias. Int Rev Neurobiol 98:151\u2013171. doi: 10.1016\/B978-0-12-381328-2.00006-7","journal-title":"Int Rev Neurobiol"},{"key":"1722_CR421","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbr.2015.04.037","volume":"290","author":"M Santana","year":"2015","unstructured":"Santana M, Palmer T, Simplicio H, Fuentes R, Petersson P (2015) Characterization of long-term motor deficits in the 6-OHDA model of Parkinson\u2019s disease in the common marmoset. Behav Brain Res 290:90\u2013101. doi: 10.1016\/j.bbr.2015.04.037","journal-title":"Behav Brain Res"},{"key":"1722_CR422","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1109\/IEMBS.2010.5626285","volume":"2010","author":"S Santaniello","year":"2010","unstructured":"Santaniello S, Gale JT, Montgomery EB, Sarma SV (2010) Modeling the effects of Deep Brain Stimulation on sensorimotor cortex in normal and MPTP conditions. Conf Proc IEEE Eng Med Biol Soc 2010:2081\u20132084. doi: 10.1109\/IEMBS.2010.5626285","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"issue":"7246","key":"1722_CR423","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature08090","volume":"459","author":"E Sasaki","year":"2009","unstructured":"Sasaki E, Suemizu H, Shimada A, Hanazawa K, Oiwa R, Kamioka M, Tomioka I, Sotomaru Y, Hirakawa R, Eto T, Shiozawa S, Maeda T, Ito M, Ito R, Kito C, Yagihashi C, Kawai K, Miyoshi H, Tanioka Y, Tamaoki N, Habu S, Okano H, Nomura T (2009) Generation of transgenic non-human primates with germline transmission. Nature 459(7246):523\u2013527. doi: 10.1038\/nature08090","journal-title":"Nature"},{"key":"1722_CR424","first-page":"47","volume-title":"Advanced Neurology","author":"JF Sassin","year":"1975","unstructured":"Sassin JF (1975) Drug-induced Dyskinesia in Monkeys. In: Meldrum BS, Marsden CD (eds) Advanced Neurology, vol 10. Raven Press, New York, pp 47\u201354"},{"issue":"11","key":"1722_CR425","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.22.11.1122","volume":"22","author":"JF Sassin","year":"1972","unstructured":"Sassin JF, Taub S, Weitzman ED (1972) Hyperkinesia and changes in behavior produced in normal monkeys by L-dopa. Neurology 22(11):1122\u20131125","journal-title":"Neurology"},{"issue":"Suppl 1","key":"1722_CR426","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","volume":"22","author":"A Sauerbier","year":"2016","unstructured":"Sauerbier A, Jenner P, Todorova A, Chaudhuri KR (2016) Non motor subtypes and Parkinson\u2019s disease. Parkinsonism Relat Disord 22(Suppl 1):S41\u201346. doi: 10.1016\/j.parkreldis.2015.09.027","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 4","key":"1722_CR427","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S1353-8020(09)70834-X","volume":"15","author":"AH Schapira","year":"2009","unstructured":"Schapira AH (2009) Neuroprotection in Parkinson\u2019s disease. Parkinsonism Relat Disord 15(Suppl 4):S41\u201343. doi: 10.1016\/S1353-8020(09)70834-X","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1722_CR428","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0002-9440(10)61113-3","volume":"160","author":"MG Schlossmacher","year":"2002","unstructured":"Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 160(5):1655\u20131667. doi: 10.1016\/S0002-9440(10)61113-3","journal-title":"Am J Pathol"},{"issue":"1\u20132","key":"1722_CR429","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-N","volume":"519","author":"JS Schneider","year":"1990","unstructured":"Schneider JS, Kovelowski CJ 2nd (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519(1\u20132):122\u2013128","journal-title":"Brain Res"},{"issue":"3","key":"1722_CR430","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/1055-8330(95)90014-4","volume":"4","author":"JS Schneider","year":"1995","unstructured":"Schneider JS, Pope-Coleman A (1995) Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 4(3):245\u2013255","journal-title":"Neurodegeneration"},{"issue":"2","key":"1722_CR431","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0006-8993(93)90049-S","volume":"615","author":"JS Schneider","year":"1993","unstructured":"Schneider JS, Roeltgen DP (1993) Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res 615(2):351\u2013354","journal-title":"Brain Res"},{"key":"1722_CR432","doi-asserted-by":"publisher","first-page":"24868","DOI":"10.1038\/srep24868","volume":"6","author":"Y Seita","year":"2016","unstructured":"Seita Y, Tsukiyama T, Iwatani C, Tsuchiya H, Matsushita J, Azami T, Okahara J, Nakamura S, Hayashi Y, Hitoshi S, Itoh Y, Imamura T, Nishimura M, Tooyama I, Miyoshi H, Saitou M, Ogasawara K, Sasaki E, Ema M (2016) Generation of transgenic cynomolgus monkeys that express green fluorescent protein throughout the whole body. Sci Rep 6:24868. doi: 10.1038\/srep24868","journal-title":"Sci Rep"},{"key":"1722_CR433","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fnagi.2016.00117","volume":"8","author":"Y Shen","year":"2016","unstructured":"Shen Y, Huang J, Liu L, Xu X, Han C, Zhang G, Jiang H, Li J, Lin Z, Xiong N, Wang T (2016) A Compendium of Preparation and Application of Stem Cells in Parkinson\u2019s Disease: current Status and Future Prospects. Front Aging Neurosci 8:117. doi: 10.3389\/fnagi.2016.00117","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1722_CR434","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","volume":"5","author":"A Shimozawa","year":"2017","unstructured":"Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M, Higuchi M, Yanai K, Hisanaga SI, Hasegawa M (2017) Propagation of pathological alpha-synuclein in marmoset brain. Acta Neuropathol Commun 5(1):12. doi: 10.1186\/s40478-017-0413-0","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1722_CR435","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0022-3565(25)12244-1","volume":"276","author":"K Shiosaki","year":"1996","unstructured":"Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M (1996) ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson\u2019s disease. J Pharmacol Exp Ther 276(1):150\u2013160","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1722_CR436","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/mds.24954","volume":"27","author":"A Siderowf","year":"2012","unstructured":"Siderowf A, Lang AE (2012) Premotor Parkinson\u2019s disease: concepts and definitions. Mov Disord 27(5):608\u2013616. doi: 10.1002\/mds.24954","journal-title":"Mov Disord"},{"issue":"8","key":"1722_CR437","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-138-8-200304150-00013","volume":"138","author":"A Siderowf","year":"2003","unstructured":"Siderowf A, Stern M (2003) Update on Parkinson disease. Ann Intern Med 138(8):651\u2013658","journal-title":"Ann Intern Med"},{"issue":"2","key":"1722_CR438","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","volume":"102","author":"JT Slevin","year":"2005","unstructured":"Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102(2):216\u2013222. doi: 10.3171\/jns.2005.102.2.0216","journal-title":"J Neurosurg"},{"issue":"1","key":"1722_CR439","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","volume":"134","author":"RJ Smeyne","year":"2005","unstructured":"Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson\u2019s disease. Brain Res Mol Brain Res 134(1):57\u201366. doi: 10.1016\/j.molbrainres.2004.09.017","journal-title":"Brain Res Mol Brain Res"},{"issue":"6","key":"1722_CR440","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/mds.870120616","volume":"12","author":"LA Smith","year":"1997","unstructured":"Smith LA, Gordin A, Jenner P, Marsden CD (1997) Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12(6):935\u2013945. doi: 10.1002\/mds.870120616","journal-title":"Mov Disord"},{"issue":"5","key":"1722_CR441","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mds.10394","volume":"18","author":"LA Smith","year":"2003","unstructured":"Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18(5):487\u2013495. doi: 10.1002\/mds.10394","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR442","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/01.WNF.0000220818.71231.DF","volume":"29","author":"LA Smith","year":"2006","unstructured":"Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P (2006) Switching from levodopa to the long-acting dopamine D2\/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 29(3):112\u2013125. doi: 10.1097\/01.WNF.0000220818.71231.DF","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"1722_CR443","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95(11):6469\u20136473","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1722_CR444","doi-asserted-by":"publisher","unstructured":"Stacy M (2009) Medical treatment of Parkinson disease. Neurol Clin 27 (3):605-631, v. doi: 10.1016\/j.ncl.2009.04.009","DOI":"10.1016\/j.ncl.2009.04.009"},{"issue":"3","key":"1722_CR445","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000438701","volume":"62","author":"MD Staudt","year":"2016","unstructured":"Staudt MD, Di Sebastiano AR, Xu H, Jog M, Schmid S, Foster P, Hebb MO (2016) Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson\u2019s Disease: a Mini-Review. Gerontology 62(3):371\u2013380. doi: 10.1159\/000438701","journal-title":"Gerontology"},{"issue":"1","key":"1722_CR446","first-page":"60","volume":"10","author":"F Stocchi","year":"1998","unstructured":"Stocchi F (1998) Continuous dopaminergic stimulation in parkinson\u2019s disease treatment. Focus on Parkinson\u2019s Disease 10(1):60\u201363","journal-title":"Focus on Parkinson\u2019s Disease"},{"issue":"6","key":"1722_CR447","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archneur.62.6.905","volume":"62","author":"F Stocchi","year":"2005","unstructured":"Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62(6):905\u2013910. doi: 10.1001\/archneur.62.6.905","journal-title":"Arch Neurol"},{"issue":"1","key":"1722_CR448","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.expneurol.2008.01.019","volume":"211","author":"KA Stockwell","year":"2008","unstructured":"Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P (2008) Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp Neurol 211(1):172\u2013179. doi: 10.1016\/j.expneurol.2008.01.019","journal-title":"Exp Neurol"},{"issue":"2","key":"1722_CR449","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.expneurol.2009.07.011","volume":"219","author":"KA Stockwell","year":"2009","unstructured":"Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, Smith LA, Olanow CW, Jenner P (2009) Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 219(2):533\u2013542. doi: 10.1016\/j.expneurol.2009.07.011","journal-title":"Exp Neurol"},{"issue":"12","key":"1722_CR450","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1089\/hum.2009.103","volume":"20","author":"X Su","year":"2009","unstructured":"Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Penticuff J, Eberling J, Federoff HJ, Forsayeth J, Bankiewicz KS (2009) Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20(12):1627\u20131640. doi: 10.1089\/hum.2009.103","journal-title":"Hum Gene Ther"},{"issue":"8","key":"1722_CR451","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/stem.1415","volume":"31","author":"M Sundberg","year":"2013","unstructured":"Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O (2013) Improved cell therapy protocols for Parkinson\u2019s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31(8):1548\u20131562. doi: 10.1002\/stem.1415","journal-title":"Stem Cells"},{"issue":"Suppl 1","key":"1722_CR452","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson\u2019s disease. J Neurochem 139(Suppl 1):318\u2013324. doi: 10.1111\/jnc.13691","journal-title":"J Neurochem"},{"issue":"1","key":"1722_CR453","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-150769","volume":"6","author":"P Tagliaferro","year":"2016","unstructured":"Tagliaferro P, Burke RE (2016) Retrograde Axonal Degeneration in Parkinson Disease. J Parkinsons Dis 6(1):1\u201315. doi: 10.3233\/JPD-150769","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1722_CR454","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1172\/JCI21137","volume":"115","author":"Y Takagi","year":"2005","unstructured":"Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115(1):102\u2013109. doi: 10.1172\/JCI21137","journal-title":"J Clin Invest"},{"issue":"4","key":"1722_CR455","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663\u2013676. doi: 10.1016\/j.cell.2006.07.024","journal-title":"Cell"},{"issue":"1","key":"1722_CR456","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.neuropharm.2009.06.030","volume":"58","author":"MK Tamim","year":"2010","unstructured":"Tamim MK, Samadi P, Morissette M, Gregoire L, Ouattara B, Levesque D, Rouillard C, Di Paolo T (2010) Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology 58(1):286\u2013296. doi: 10.1016\/j.neuropharm.2009.06.030","journal-title":"Neuropharmacology"},{"issue":"2","key":"1722_CR457","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(88)90322-6","volume":"156","author":"JA Temlett","year":"1988","unstructured":"Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD (1988) The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 156(2):197\u2013206","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1722_CR458","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mds.870040307","volume":"4","author":"JA Temlett","year":"1989","unstructured":"Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X (1989) Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson\u2019s disease. Mov Disord 4(3):261\u2013265. doi: 10.1002\/mds.870040307","journal-title":"Mov Disord"},{"issue":"8\u20139","key":"1722_CR459","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1177\/0301006615596868","volume":"44","author":"LV Tereshchenko","year":"2015","unstructured":"Tereshchenko LV, Anisimov VN, Shul\u2019govsky VV, Latanov AV (2015) Early Changes in Saccadic Eye Movement in Hemiparkinsonian MPTP-Treated Monkeys. Perception 44(8\u20139):1054\u20131063. doi: 10.1177\/0301006615596868","journal-title":"Perception"},{"issue":"Pt 6","key":"1722_CR460","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/brain\/awm097","volume":"130","author":"TC Thannickal","year":"2007","unstructured":"Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson\u2019s disease. Brain 130(Pt 6):1586\u20131595. doi: 10.1093\/brain\/awm097","journal-title":"Brain"},{"issue":"5","key":"1722_CR461","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/practneurol-2013-000741","volume":"14","author":"A Todorova","year":"2014","unstructured":"Todorova A, Jenner P, Ray Chaudhuri K (2014) Non-motor Parkinson\u2019s: integral to motor Parkinson\u2019s, yet often neglected. Pract Neurol 14(5):310\u2013322. doi: 10.1136\/practneurol-2013-000741","journal-title":"Pract Neurol"},{"issue":"2","key":"1722_CR462","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.1099","volume":"50","author":"DM Togasaki","year":"2001","unstructured":"Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW (2001) Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 50(2):254\u2013257","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"1722_CR463","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jneumeth.2004.12.010","volume":"145","author":"DM Togasaki","year":"2005","unstructured":"Togasaki DM, Hsu A, Samant M, Farzan B, DeLanney LE, Langston JW, Di Monte DA, Quik M (2005a) The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods 145(1\u20132):159\u2013166. doi: 10.1016\/j.jneumeth.2004.12.010","journal-title":"J Neurosci Methods"},{"issue":"3","key":"1722_CR464","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neuropharm.2004.10.009","volume":"48","author":"DM Togasaki","year":"2005","unstructured":"Togasaki DM, Protell P, Tan LC, Langston JW, Di Monte DA, Quik M (2005b) Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology 48(3):398\u2013405. doi: 10.1016\/j.neuropharm.2004.10.009","journal-title":"Neuropharmacology"},{"issue":"6512","key":"1722_CR465","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/373335a0","volume":"373","author":"A Tomac","year":"1995","unstructured":"Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373(6512):335\u2013339. doi: 10.1038\/373335a0","journal-title":"Nature"},{"issue":"1","key":"1722_CR466","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2005.11.026","volume":"169","author":"L Truong","year":"2006","unstructured":"Truong L, Allbutt H, Kassiou M, Henderson JM (2006) Developing a preclinical model of Parkinson\u2019s disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 169(1):1\u20139. doi: 10.1016\/j.bbr.2005.11.026","journal-title":"Behav Brain Res"},{"key":"1722_CR467","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1686-y","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna). doi: 10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"1722_CR468","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5(1):107\u2013110","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1722_CR469","first-page":"37","volume":"2","author":"U Ungerstedt","year":"1976","unstructured":"Ungerstedt U (1976) 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther B 2(1):37\u201340","journal-title":"Pharmacol Ther B"},{"issue":"Pt 19","key":"1722_CR470","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1242\/jcs.054783","volume":"122","author":"J Utikal","year":"2009","unstructured":"Utikal J, Maherali N, Kulalert W, Hochedlinger K (2009) Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 122(Pt 19):3502\u20133510. doi: 10.1242\/jcs.054783","journal-title":"J Cell Sci"},{"key":"1722_CR471","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/7854_2014_310","volume":"22","author":"A Perren Van der","year":"2015","unstructured":"Van der Perren A, Van den Haute C, Baekelandt V (2015) Viral vector-based models of Parkinson\u2019s disease. Curr Top Behav Neurosci 22:271\u2013301. doi: 10.1007\/7854_2014_310","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"1722_CR472","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0306-4522(94)90006-X","volume":"63","author":"M Varastet","year":"1994","unstructured":"Varastet M, Riche D, Maziere M, Hantraye P (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson\u2019s disease. Neuroscience 63(1):47\u201356","journal-title":"Neuroscience"},{"issue":"8","key":"1722_CR473","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.5665\/SLEEP.1174","volume":"34","author":"PS Verhave","year":"2011","unstructured":"Verhave PS, Jongsma MJ, Van den Berg RM, Vis JC, Vanwersch RA, Smit AB, Van Someren EJ, Philippens IH (2011) REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep 34(8):1119\u20131125. doi: 10.5665\/SLEEP.1174","journal-title":"Sleep"},{"issue":"4","key":"1722_CR474","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.neuropharm.2011.11.016","volume":"62","author":"PS Verhave","year":"2012","unstructured":"Verhave PS, Jongsma MJ, Van Den Berg RM, Vanwersch RA, Smit AB, Philippens IH (2012) Neuroprotective effects of riluzole in early phase Parkinson\u2019s disease on clinically relevant parameters in the marmoset MPTP model. Neuropharmacology 62(4):1700\u20131707. doi: 10.1016\/j.neuropharm.2011.11.016","journal-title":"Neuropharmacology"},{"key":"1722_CR475","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuint.2016.11.009","volume":"102","author":"Y Vermeiren","year":"2017","unstructured":"Vermeiren Y, De Deyn PP (2017) Targeting the norepinephrinergic system in Parkinson\u2019s disease and related disorders: the locus coeruleus story. Neurochem Int 102:22\u201332. doi: 10.1016\/j.neuint.2016.11.009","journal-title":"Neurochem Int"},{"key":"1722_CR476","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jneumeth.2015.07.025","volume":"255","author":"SC Vermilyea","year":"2015","unstructured":"Vermilyea SC, Emborg ME (2015) alpha-Synuclein and nonhuman primate models of Parkinson\u2019s disease. J Neurosci Methods 255:38\u201351. doi: 10.1016\/j.jneumeth.2015.07.025","journal-title":"J Neurosci Methods"},{"issue":"8","key":"1722_CR477","doi-asserted-by":"publisher","first-page":"e23952","DOI":"10.1371\/journal.pone.0023952","volume":"6","author":"J Vezoli","year":"2011","unstructured":"Vezoli J, Fifel K, Leviel V, Dehay C, Kennedy H, Cooper HM, Gronfier C, Procyk E (2011) Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson\u2019s disease. PLoS ONE 6(8):e23952. doi: 10.1371\/journal.pone.0023952","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"1722_CR478","first-page":"13","volume":"14","author":"M Vidailhet","year":"1999","unstructured":"Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y (1999) The phenomenology of L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 14(Suppl 1):13\u201318","journal-title":"Mov Disord"},{"issue":"3","key":"1722_CR479","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ana.410130304","volume":"13","author":"PJ Whitehouse","year":"1983","unstructured":"Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL (1983) Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13(3):243\u2013248. doi: 10.1002\/ana.410130304","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"1722_CR480","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol 26(Suppl 1):S1\u201358. doi: 10.1007\/s10654-011-9581-6","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"1722_CR481","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D (2017) alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23(2):1\u201313. doi: 10.1038\/nm.4269","journal-title":"Nat Med"},{"issue":"7","key":"1722_CR482","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jnnp-2015-312036","volume":"87","author":"B Xiao","year":"2016","unstructured":"Xiao B, Ng HH, Takahashi R, Tan EK (2016) Induced pluripotent stem cells in Parkinson\u2019s disease: scientific and clinical challenges. J Neurol Neurosurg Psychiatry 87(7):697\u2013702. doi: 10.1136\/jnnp-2015-312036","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1722_CR483","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.expneurol.2010.08.007","volume":"228","author":"W Xu","year":"2011","unstructured":"Xu W, Miocinovic S, Zhang J, Baker KB, McIntyre CC, Vitek JL (2011) Dissociation of motor symptoms during deep brain stimulation of the subthalamic nucleus in the region of the internal capsule. Exp Neurol 228(2):294\u2013297. doi: 10.1016\/j.expneurol.2010.08.007","journal-title":"Exp Neurol"},{"issue":"1","key":"1722_CR484","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/cpr.12229","volume":"49","author":"X Xu","year":"2016","unstructured":"Xu X, Huang J, Li J, Liu L, Han C, Shen Y, Zhang G, Jiang H, Lin Z, Xiong N, Wang T (2016) Induced pluripotent stem cells and Parkinson\u2019s disease: modelling and treatment. Cell Prolif 49(1):14\u201326. doi: 10.1111\/cpr.12229","journal-title":"Cell Prolif"},{"issue":"2","key":"1722_CR485","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/hum.2005.16.262","volume":"16","author":"M Yamada","year":"2005","unstructured":"Yamada M, Mizuno Y, Mochizuki H (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson\u2019s disease. Hum Gene Ther 16(2):262\u2013270. doi: 10.1089\/hum.2005.16.262","journal-title":"Hum Gene Ther"},{"issue":"7197","key":"1722_CR486","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nature06975","volume":"453","author":"SH Yang","year":"2008","unstructured":"Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW (2008) Towards a transgenic model of Huntington\u2019s disease in a non-human primate. Nature 453(7197):921\u2013924. doi: 10.1038\/nature06975","journal-title":"Nature"},{"issue":"10","key":"1722_CR487","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jgm.1377","volume":"11","author":"X Yang","year":"2009","unstructured":"Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Chtarto A, Levivier M, Brotchi J, Michotte Y, Baekelandt V, Sarre S, Tenenbaum L (2009) Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson\u2019s disease rat model. J Gene Med 11(10):899\u2013912. doi: 10.1002\/jgm.1377","journal-title":"J Gene Med"},{"issue":"2","key":"1722_CR488","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neuroscience.2006.09.052","volume":"144","author":"T Yasuda","year":"2007","unstructured":"Yasuda T, Miyachi S, Kitagawa R, Wada K, Nihira T, Ren YR, Hirai Y, Ageyama N, Terao K, Shimada T, Takada M, Mizuno Y, Mochizuki H (2007) Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. Neuroscience 144(2):743\u2013753. doi: 10.1016\/j.neuroscience.2006.09.052","journal-title":"Neuroscience"},{"issue":"4","key":"1722_CR489","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0028-3908(93)90151-R","volume":"32","author":"N Yoshimura","year":"1993","unstructured":"Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O (1993) The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32(4):315\u2013321","journal-title":"Neuropharmacology"},{"issue":"1","key":"1722_CR490","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(24)37579-2","volume":"286","author":"N Yoshimura","year":"1998","unstructured":"Yoshimura N, Mizuta E, Yoshida O, Kuno S (1998) Therapeutic effects of dopamine D1\/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 286(1):228\u2013233","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"1722_CR491","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.1016\/S1353-8020(08)70017-8","volume":"13","author":"MB Youdim","year":"2007","unstructured":"Youdim MB, Geldenhuys WJ, Van der Schyf CJ (2007) Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson\u2019s disease? Parkinsonism Relat Disord 13(Suppl 3):S281\u2013291. doi: 10.1016\/S1353-8020(08)70017-8","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1722_CR492","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5625\/lar.2015.31.4.155","volume":"31","author":"JW Yun","year":"2015","unstructured":"Yun JW, Ahn JB, Kang BC (2015) Modeling Parkinson\u2019s disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care. Lab Anim Res 31(4):155\u2013165. doi: 10.5625\/lar.2015.31.4.155","journal-title":"Lab Anim Res"},{"issue":"10","key":"1722_CR493","doi-asserted-by":"crossref","first-page":"B473","DOI":"10.1093\/gerona\/55.10.B473","volume":"55","author":"Z Zhang","year":"2000","unstructured":"Zhang Z, Andersen A, Smith C, Grondin R, Gerhardt G, Gash D (2000) Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J Gerontol A Biol Sci Med Sci 55(10):B473\u2013480","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"1722_CR494","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/JPD-140372","volume":"4","author":"P Zis","year":"2014","unstructured":"Zis P, Rizos A, Martinez-Martin P, Pal S, Silverdale M, Sharma JC, Sauerbier A, Chaudhuri KR (2014) Non-motor symptoms profile and burden in drug naive versus long-term Parkinson\u2019s disease patients. J Parkinsons Dis 4(3):541\u2013547. doi: 10.3233\/JPD-140372","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"1722_CR495","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/ene.12733","volume":"22","author":"P Zis","year":"2015","unstructured":"Zis P, Martinez-Martin P, Sauerbier A, Rizos A, Sharma JC, Worth PF, Sophia R, Silverdale M, Chaudhuri KR (2015) Non-motor symptoms burden in treated and untreated early Parkinson\u2019s disease patients: argument for non-motor subtypes. Eur J Neurol 22(8):1145\u20131150. doi: 10.1111\/ene.12733","journal-title":"Eur J Neurol"},{"key":"1722_CR496","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fncom.2015.00093","volume":"9","author":"LM Zitella","year":"2015","unstructured":"Zitella LM, Teplitzky BA, Yager P, Hudson HM, Brintz K, Duchin Y, Harel N, Vitek JL, Baker KB, Johnson MD (2015) Subject-specific computational modeling of DBS in the PPTg area. Front Comput Neurosci 9:93. doi: 10.3389\/fncom.2015.00093","journal-title":"Front Comput Neurosci"},{"issue":"8","key":"1722_CR497","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrn1727","volume":"6","author":"LS Zweifel","year":"2005","unstructured":"Zweifel LS, Kuruvilla R, Ginty DD (2005) Functions and mechanisms of retrograde neurotrophin signalling. Nat Rev Neurosci 6(8):615\u2013625. doi: 10.1038\/nrn1727","journal-title":"Nat Rev Neurosci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-017-1722-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1722-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1722-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T21:31:24Z","timestamp":1750195884000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-017-1722-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,8]]},"references-count":497,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1007\/s00702-017-1722-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,8]]}}}